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The severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) was 
identified as the causative agent of SARS. Up till now, there is no single proven 
effective method recommended for the treatment of SARS. This research project 
explores the potential of the Nucleocapsid (N) and the Spike (S) protein of SARS 
virus for vaccine development. 
S and N proteins, which are the typical structural proteins of coronavirus, were 
chosen in this study based on their unique features. S protein is a membrane 
glycoprotein responsible for receptor binding and entries into the host cells while N 
protein probably involves in stimulating cytotoxic T lymphocytes. Full-length N 
protein and the truncated S fragments, i.e. S m o o and S401-1000，were our main focus of 
this study. 
Both prokaryotic (E.coli) and eukaryotic (baculovirus) systems were used for 
expression to evaluate whether the posttranslational modifications or protein folding 
will affect the immunoreactivies of our target proteins. Si-400，S401-1000 and N proteins 
were first expressed in E.coli and were designated as rSi_4oo(E)，rS4oi-1000(E) and rN(E) 
respectively. The immunoreactivies of rS4oi-iooo(E) and rN(E) were highly specific 
when reacting against SARS convalescent-phase patients sera. S401-1000 and N were 
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then expressed in baculovims, AcNPV and BmNPV, designated as rS4oi-iooo(ACN) 
and rN(BMN) respectively. We observed that both rN(BMN) and rN(E) were strong 
immunogens and no difference could be detected between their immunoreactivities. 
However, although rS4oi-iooo(E) can react more specifically with SARS patient sera 
than rS4oi-iooo(ACN), the immunoreactivity of rS4oi-iooo(ACN) appeared to be stronger 
than rS4o 1-1000(E) and both N proteins when reacting against horse anti-SARS 
acute-phase serum. These results suggest that (1) S401-1000 and N may probably be the 
good candidates for SARS vaccine development; (2) from a virus infection viewpoint, 
S401-1000 may be the essential immunogen in the acute-phase of SARS-CoV infection 
while N may replaced the S protein in the convalesce-phase; and (3) S401-1000 appears 
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Chapter 1 Introduction 
1.1 Background of SARS and epidemiology 
The earliest cases of severe atypical pneumonia of unknown etiology were 
believed to first occur in mid-November 2002 in Guangdong Province, China. Many 
similar cases of this disease in different parts of the world could be traced through 
multiple chains of transmission to an incident case of an infected medical doctor from 
Guangdong who checked into room 911 on the 9th floor of the Metropole Hotel in 
Hong Kong on 21 February 2003. Visitors to the hospital were responsible for 
spreading all the earliest and most severe outbreaks in Toronto, Hong Kong, Viet Nam, 
and Singapore. Less than a month later in mid-March 2003, the World Health 
Organization (WHO) issued a global alert for this illness and designated it as "severe 
acute respiratory syndrome" (SARS). 
1.2 SARS symptoms and infected regions 
The incubation period for SARS infection is usually from 2 to 7 days. Infection 
is usually characterized by fever, a dry nonproductive cough and followed by 
shortness of breath. Changes in chest X-ray, indicative of pneumonia, also occur 
subsequently. Death from progressive respiratory failure occurs in about 3% to nearly 
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10% of the cases (Centers for Diseases Control and Prevention, 2003). By the end of 
July 2003，over 8000 cumulative SARS cases and 774 SARS-related deaths were 
reported to WHO from over 25 countries around the world (Table 1.1). 
1.3 SARS virus 
Attempts to identify the cause of the SARS outbreak were successful during the 
third week of March 2003，when laboratories in the United States, Canada, Germany 
and Hong Kong isolated a novel coronavims (SARS-CoV) from SARS patients (Paul 
al., 2003). SARS-CoV RNA could be frequently detected in respiratory specimens 
and the convalescent-phase SARS patients had antibodies that could react with the 
SARS-CoV. 
The coronaviruses (order Nidovirales’ family Coronaviridae, genus Coronavims) 
are a diverse group of large, enveloped, positive-stranded RNA viruses that cause 
respiratory and enteric diseases in humans and other animals. At around 30,000 
nucleotides (nt)，their genome is the largest found in any of the RNA viruses. 
The genome size of the SARS coronavims is around 29 kb and has 11 open 
reading frames compose of a stable region encoding an RNA-dependent RNA 
polymerase with 2 open reading frames, a variable region representing 4 coding 
2 
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Cumulative number of cases 
Med.-n Numbe- Nu^ ^^ber ^ ^ ^ 
Areas Female Male Total age of ratio imported effected first lest 
(range) deaths' cases v probable probable 
( 彻 〉 、 * case case 
A u s t r a l i a 4 2 6 0 0 6 ( 1 0 0 ) 0 <0) 2 6 - F e b - 0 3 l - A p r - 0 3 
C a n a d a 1 5 1 1 0 0 2 5 1 4 3 17 5 ( 2 ) 1 0 9 ( 4 3 ) 2 3 - F e b - 0 3 1 2 - 3 u n - 0 3 
C h i n 。 2 6 7 4 2 6 0 7 5 3 2 7 ' ' 3 4 9 7 A p p t l b l e 
C h i n a , H o n g 
A d ^ ^ i ^ ? ^ 9 ” 7 7 8 X 7 5 5 工々。。片 2 9 9 17 A p p ^ l l l l e ^BS ( 2 2 ) 1 5 - P e b - 0 3 ^ l - M . y -
R e g i o n 
C h i n a , M a c a o 
A d m i n i f t ^ a ^ i f J 0 1 1 28 0 0 1 ( 1 0 0 ) 0 ( 0 〉 5 - M a y - 0 3 5 - M a y - 0 3 
R e g i o n 
C h i n a , T a i w a n 2 1 8 1 2 8 346*= 37 1 1 2 1 ( 6 ) 6 8 ( 2 0 ) 2 5 - F e b - 0 3 1 5 - J u n - 0 3 
F r a n c e 1 6 7 々9思 1 14 7 ( 1 0 0 〉 2 (29)^ 3 - M a y - 0 3 
G e r m a n y 4 5 9 • 0 9 ( 1 0 0 ) 1 ( 1 1 ) 9 - M a r - 0 3 6 - M a y - 0 3 
I n d i a 0 3 3 0 0 3 ( 1 0 0 ) 0 ( 0 ) 2 5 - A p r - 0 3 6 - M a y - 0 3 
I n d o n e s i a 0 2 2 。 0 2 ( 1 0 0 ) 0 ( 0 ) 6 - A p r - 0 3 1 7 - A p r - 0 3 
I t a l y 1 3 4 ( 2 5 - 5 4 ) ° 0 4 ( 1 0 0 ) 0 (O) 2 0 - A p r - 0 3 
K u w a i t 1 0 1 5 0 0 0 1 ( 1 0 0 ) 0 ( 0 ) 9 - A p r - 0 3 9 - A p r - 0 3 
M a l a y s i a 1 4 5 。。日衆- 2 4 0 5 ( 1 0 0 ) 0 ( 0 ) 丄……J"; 2 2 - A p r - 0 3 
M o n g o l i a 8 1 9 0 0 8 ( 8 9 ) 0 ( 0 ) 6 - M a y - 0 3 
N o w Z e a l a n d 1 0 1 6 7 0 0 1 ( 1 0 0 ) 0 ( 0 ) 2 0 - A p r - 0 3 2 0 - A p r - 0 3 
P h i l i p p i n e s 6 6 14 2 14 7 ( 5 0 ) 4 ( 2 9 ) 2 5 - F o b - 0 3 5 - M a y - 0 3 
R叩 IVbJl^nO: 0 1 1 56 0 0 1 ( 1 0 0 ) 0 ( 0 ) 2 7 - F e b - 0 3 2 7 - F e b - Q 3 
" P U ^ C r 二 0 3 3 卯8(of - 0 0 3 ( 1 0 0 ) 0 ( 0 ) 2 5 - A p r - 0 3 
R o m a n i a 0 1 1 5 2 0 0 1 ( 1 0 0 ) 0 ( 0 ) 
Fed'V ' rat Ign 。 1 1 2 5 0 0 A二ratfale 。（。> S . M a y - 0 3 
S i n g a p o r e 1 6 1 7 7 2 3 8 3 3 14 8 ( 3 ) 9 7 ( 4 1 ) 2 5 - F e b - 0 3 5 - M a y - 0 3 
S o u t h A f r i c a 0 1 1 6 2 1 1 0 0 1 ( 1 0 0 ) 0 ( 0 ) 3 - A p r - 0 3 3 - A p r - 0 3 
S p a i n 0 1 1 3 3 0 0 1 ( 1 0 0 ) 0 ( 0 ) 2 6 - M a j - - 2 6 - M a j - -
S w e d e n 3 2 5 〜々(^。广 o O S ( 1 0 0 ) O ( 0 ) 2 8 - M a j - 2 3 - A p r - 0 3 
S w i t z e r l a n d 0 1 1 35 0 0 1 ( 1 0 0 ) 0 ( 0 ) 9 - M a r - 0 3 9 - M a r - 0 3 
T h a i l a n d 5 4 9 ^ 7 9 ) ' 2 2 2 9 ( 1 0 0 ) 1 ( i i ) d 2 7 - M a y -
Kin^ 'gdom ^ 2 4 % 斤 - 0 0 4 ( 1 0 0 ) 0 ( 0 ) l - M a r - 0 3 l - A p r - 0 3 
U n i t e d S t a t e s 1 3 14 2 7 ^ t ^ ? ' 0 0 2 7 <100〉 0 ( 0 ) 2 4 - F e b - 0 3 I S - J u l : 
oJ； 0 3 * 
V i e t N a m 3 9 24 6 3 们，(/广 5 8 1 ( 2 ) 3 6 ( 5 7 ) 2 3 - F e b - 0 3 1 4 - A p r - 0 3 
Total 8096 774 9.6 142 1706 
Table 1.1 Summary of probable SARS cases with onset of illness from November 
2002 to 31 July 2003. (Adopted from World Health Organization at 
http://www.who.int/csr/sars/countrv/table2Q04 04 21/qu/) 
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sequences for viral structural genes, spike (S protein), envelop (E protein), membrane 
(M protein), and nucleocapsid (N protein). (Figure 1.1) (Wang et al., 2003). A 
phylogenetic analysis of the SARS-CoV replicase gene, using a distantly related 
torovirus as an outgroup, demonstrated that, despite a number of unique features, 
SARS-CoV is most closely related, but not belong to group 2 coronavirus (Figure 1.2) 
(Eric et a/.，2003). 
1.4 Treatment for SARS at present 
For the treatment of SARS, a number of medicines have been tried including 
antibiotics to treat known bacterial agents for atypical pneumonia. Since the diagnosis 
of atypical pneumonia is in itself a challenge, it should be assisted by careful clinical 
assessment. Given the likely absence of auscultatory signs, accurate measurement of 
respiratory rate and oxygen saturation is required. Chest radiography is also useful in 
diagnosis and should be considered even in the absence of respiratory symptoms 
(World Health Organization, 2003). In certain cases, antiviral agents, such as 
oseltamivir or ribavirin with a combination of steroids, have also been included in the 
therapy. However, all these treatment did not appear to be effective. As yet there is not 
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Figure 1.1 Overview of the SARS-CoV genome organization and expression. The 
genome contains two nonstructural proteins ORF la and ORF lb at the 5'-temimal. In 
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Figure 1.2 Phylogenetic analysis of coronavirus replicase genes. SARS-CoV replicase 
ORPlb amino acid sequences were compared with those from viruses representing 




1.5 Vaccine development is a more effective way to fight against SARS 
Vims attacks host cells usually by destroying cells or altering the function of 
normal cells, such as causing cell membrane fusion. This will help the viral envelope 
proteins to be inserted into the plasma membrane of the host cell. Cell-to-cell 
transmission of the virus will be enhanced by this mechanism. The host immune 
response to a virus appears first during the primary infection. The specific immune 
response that is effective against viral infection involves both humoral and 
cell-mediated response. In humoral response, virus or virus-infected cells can 
stimulate B lymphocytes to produce antibodies. The cell-mediated immunity refers to 
the recognition or killing of the virus and the vims-infected cells by cytotoxic T 
lymphocytes, natural killer cells and antiviral macrophages. 
Coronavimses previously described have not been observed to cause lethal 
disease in humans. But their pathogenicity in domestic animal species has been well 
documented, and experimental vaccines developed for animals have provided insights 
into mechanisms of protective immunity (Saif et ai, 1993). Studies of the immune 
response to coronavimses suggest that both humoral and cell-mediated immunity 
contribute to long-term protection (Sestak et al., 1999). Clinical observations in SARS 
patients have demonstrated that a profile of specific antibodies exists. The 
SARS-specific IgG antibody persisted for a long time, but the SARS-specific IgM 
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remained measurable for a much shorter period (Figure 1.3)，suggesting that IgG 
antibody to SARS-CoV may represent the primary humoral immune response 
protecting patients against SARS. One of our preliminary results suggested that the 
cellular immune response also exists in the SARS patients. During the primary 
immune response, memory cells will be generated together with the native T cells and 
B cells. For the subsequent exposure to the virus or viral antigen, the memory cells 
will proliferate rapidly to generate large amount of cytotoxic T cells. Based on this 
assumption, we used the lymphocyte stimulation test to assay T cell response to N 
protein in vitro. When the N protein concentration reached lOug/ml, all the T cells 
from patient proliferate more rapidly than that from normal person (Figure 1.4). 
Therefore, a successful immunogen for the treatment of SARS should have the 
ability to activate both immune responses. 
1.6 Vaccine candidates 
Different viruses often cause different immunoresponses. However, the 
antigenicities and roles of SARS-CoV viral proteins in immunity remain unclear. In 
this study, two major viral structural proteins, truncated S protein and N protein, were 
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Figure 1.3 Changing titers of IgM and IgG antibodies to SARS-CoV from the outset 
of illness through the convalescent phase from 20 patients from Guangdong province, 
China. IgM and IgG were measured at weeks 1，2, 3，4，8’ and 12; the mean IgG titer 
was 1:40 at week 2，1:256 at week 3，1:368 at week 4，1:640 at week 8, and 1:640 at 
week 12. The mean IgM titer was 1:120 at week 2, 1:320 at week 3，1:160 at week 4, 
and 1:40 at week 8. The cutoff value for a positive result was 1:10, and patients with 
negative results were considered to have a titer of 0 for the calculation of the mean 





O ： Normal person T-cell. 
i N = 4 
0) 350 -u 
I 300 -
^ 250 - / ^ — _ _ ^ / 
(0 / T 
1 咖- / / K - _ _ 丄 
！I 160 - / “ � " � � 
| i��_ ^^ 
60 r 1 1 1 i • 
0 2 4 6 8 10 
Concentration of N Protein ( j u g/ mL) 
Figure 1.4 Lymphocyte stimulation test which measures T cells proliferation rate both 
from SARS patients and normal persons by different N protein concentrations from 0 
fi g/mL to lOyCZ g/mL. ^H-Thymidine incorporation into DNA was used as an index to 
measure cell proliferation. This graph shows that T cells from SARS patients 
proliferated more rapidly than that from normal persons. 
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1.6.1 Truncated S protein as a vaccine candidate 
The spike protein of the SARS-CoV is a large type-I transmembrane 
glycoprotein which is responsible for receptor binding and membrane fusion. The 
genome sequence of the SARS-CoV predicts that the S protein should have 1255 
amino acids with 23 potential N-linked glycosylation sites. The S protein can be 
structurally divided into the N-terminal SI and C-terminal S2 subunits. Unlike other 
coronaviruses, such as human coronavirus (HCoV) 229E, in which the S protein is 
cleaved into SI and S2 subunits, the S protein of SARS-CoV is not cleaved (Zhou et 
al” 2004). It has recently been demonstrated that the binding of the SI domain to the 
angiotensin converting enzyme 2 (ACE2) receptor on host cells is responsible for 
viral entry (Li et al, 2003). The S2 domain contains the membrane-anchoring and 
fusion region, which plays a key role in virus assembly and entry. 
In infectious bronchitis vims (IBV), the SI glycoprotein consisting of l，654bp， 
which induces virus- neutralizing and hemagglutination-inhibiting antibodies, was 
found to be more antigenic than either N or M proteins (Zhou et al.，2003). Therefore, 
we target to express SI from 1 to 400amino acid and see if it could elicit an immune 
response against the SARS-CoV. 
Other studies have identified some antigenic determinants on the S2 domain of 
SARS-CoV S protein. Examples of these include the S2 fragment aa803-aa828 
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(Zhang et al., 2004) and aa485-aa625 (Zhou et al., 2004), which have the capability in 
inducing neutralizing antibodies, and aa599-aa620 (Wang et al., 2003) which can 
react against SARS patients sera in ELISA. Therefore we have also chosen the 
fragment from aa401-aal000 in S2 for expressing in this study. 
1.6.2 Full-length N protein as a vaccine candidate 
N protein is a highly charged basic protein of 422-amino acid. It has seven 
successive hydrophobic residues with a highly conserved motif in the N-terminal 
(Marra et al., 2003). Some studies have shown that the N protein is a strong 
immunogen in several coronaviruses. The cellular immune response against N protein 
of some animal coronavims could enhance the recovery from virus infection 
(Glansbeek et al.’ 2002; Wasmoen et al, 1995; Wesseling et al, 1993). N protein is a 
highly abundant and relatively conserved antigen. It may be involved in stimulating 
cytotoxic T lymphocytes. It has been reported that N protein accumulates even before 
it is packaged in the mature virus. A cellular immune response elicited early in 
infection by internal viral proteins could therefore be an important defense 
mechanism. In this study, we also targeted to express the full-length N protein in both 
E.coli and baculovirus. 
1.7 E. coli expression system 
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The advantages of using E. coli for heterologous gene expression include the 
ease of growth and manipulation of this organism, the availability of dozens of 
vectors and host strains that have been developed for maximizing expression, a wealth 
of knowledge about the genetics and physiology of E. coli, and high production yield. 
The main disadvantages of E. coli expression are its inability to carry out complex 
post-translational modifications typical of eukaryotes, such as glycosylation, 
phosphorylation, specific proteolytic processing and disulfide bonds formation. 
Another limitation is the formation of inclusion bodies which produces 
non-functioning protein due to misfolding and aggregation. 
The S protein of SARS-CoV has been shown to have a higher molecular weight 
than the theoretical one deduced from its gene sequence. This indicates that it has a 
large degree of modifications after translation. By in-gel digestion, S protein was 
found to have four glycosylation sites (Ying et al., 2004). Whereas the 
phosphorylation of N protein is a well documented phenomenon in many 
coronavimses such as murine hepatitis virus (MHV), infectious bronchitis virus (LBV), 
bovine coronavirus (BCV) and porcine epidemic diarrhoea virus (PEDV) (Stohlman 
et al., 1979; Wilbur et al., 1986; Lomniczi et al., 1981; King et al., 1982; Utiger et al., 
1995). Although the functional significance in S and N protein modification is still 
under investigation, it will be of interest to express these proteins in E.coli to evaluate 
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whether modifications play a role on the immunogenecity of these proteins. 
1.8 Baculovirus expression system 
1.8.1 Characteristics of baculovirus 
Baculoviruses are a diverse group of closed-circular double-stranded DNA 
viruses of the family Baculoviridae, which are found mostly in insects. The baculo 
portion of the name refers to the rod-shaped capsids of the virus particles (0’ Reilly et 
al., 1994). The Baculoviridae can be divided into two sub-families: the 
Eubaculovirinae (occluded baculoviruses) and the Nudibaculovirinae (non-occulded 
baculoviruses). The Eubaculovirinae produce crystalline proteinaceous structures 
called occlusion bodies which are absent in the Nudibaculovirinae (Vialard et al., 
1995). The Eubaculovirinae subfamily is made up of two genera: granulosis viruses 
(GVs) and nuclear polyhedrosis viruses (NPVs). The viruses used in this study, the 
Bomhyx mori Nuclear Polyhedrosis Virus (BmNPV) and Autographa californica 
Nuclear Polyhedrosis Virus (AcMNPV), are NPV. They are both commonly used 
baculovirus vectors for recombinant protein expression. They will be the focus of the 
following discussion. Most baculoviruses are very host-specific, and the majority of 
Eubaculovirinae have been isolated from larvae of the Lepidoptera family (for 
example, moths and butterflies). 
1.8.2 Infection cycle of baculovirus 
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The occlusion bodies containing mature virus particles are taken up by a 
susceptible larval host as food contaminants. The alkaline environment of the larval 
midgut dissolves the occlusion bodies and releases the virus particles (Kelly 1982). 
Primary infection of the midgut epithelial cells occurs through a receptor-mediated 
membrane fusion process. The nucleocapsids are targeted to the nucleus where 
replication and transcription of the viral DNA occur. Budding viruses from the 
initially infected cells cause secondary infection to adjacent cells through a 
receptor-mediated adsorptive endocytosis mechanism. At a late stage of the infection 
process, the mature virus particles are multiply packed into occlusion bodies which 
comprise mainly of a protein called polyhedrin. Finally, the infected larva dies and 
disintegrates. The occluded viruses, which are protected by the occlusion bodies, are 
dispersed into the environment from the dead bodies. The occlusion bodies may be 
consumed by another larva, thereby reinitiating a new cycle of infection (Figure 1.5). 
1.8.3 Control of viral gene expression in virus-infected cells 
Baculovirus gene expression is regulated in a cascade-like fashion. The temporal 
regulation allows the grouping of baculoviral genes into three phases during infection: 
early (E), late (L), and very late (VL). The E genes are transcribed prior to viral DNA 
replication and generally encode proteins with regulatory functions. The L genes are 
activated before the VL genes and are maximally transcribed between 12 and 24 
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Figure 1.5 Life cycle of a baculovirus in an infected insect cell, including primary 
infection and secondary infection. 
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hours post-infection. This catalogue of genes encodes structural proteins of the 
budding virus and occlusion-derived virus. The VL genes, which are under control of 
strong promoters, are hyper-expressed following the activation of the L genes and 
remain active from 48 hours post-infection onward. VL proteins are those involved in 
the process of occlusion body formation and cell lysis. 
1.8.4 Merits of baculovims expression system 
Baculovirus expression system has been successfully employed to express 
biologically active recombinant proteins for agriculture and pharmaceutical use, such 
as human a -interferon (Maeda et al., 1985), human hepatocyte growth factor (Yee et 
al., 1993), human growth hormone (Kadono-Okuda et al, 1995), human 
granulocyte-macrophage colony-stimulating factor (Shi et al” 1996) and grass carp 
growth hormone (Ho et al.’ 1998). There are a number of advantages in using 
baculovirus as an expression vector (Maeda et al., 1989, 1994). Firstly, being 
eukaryotic origin, the insect cells can correctly fold and modify the expressed foreign 
proteins with their biological activities retained. Secondly, the double-stranded DNA 
genome of the virus can be easily manipulated by general molecular biology 
techniques and the rod-shaped viral capsid is rather “flexible，，in accommodating large 
DNA insert. In this regard, the polyhedrin gene (polh) is the best choice because it is 
non-essential for viral reproduction and is driven by a powerful promoter. Moreover, 
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the occlusion-negative trait is a good marker to indicate the successful insertion of a 
foreign gene under the control of polh promoter. Thirdly, the recombinant 
baculoviruses cannot survive in the environment owing to the lack of protection by 
occlusion bodies, this posing less biohazards. However, the construction of a 
recombinant baculovirus takes longer and is generally more complex than 
constructing an E. coli expression vector. 
1.9 Aim of study 
In this study, we will attempt to express the SARS structural proteins, S protein 
including Si-400 (1-400 a. a) and S401-1000 (401-1000 a. a), and full-length N protein in 
E.coli and baculovirus expression systems. The immunoreactivities of these 
recombinant proteins will be characterized and evaluated with respect to their abilities 
to elicit immunoresponse against the SARS-CoV. 
18 
Bacterial expression and purification 
Chapter 2 Bacterial expression and purification of rSi^oo(E), rS4oi.iooo(E) and 
rN(E) 
2.1 Introduction 
The prokaryotic expression system, such as E.coli, can produce large quantity of 
recombinant protein with a relatively simple and quick procedure. At the beginning of 
this project, few studies of the SARS structural proteins have been done to ascertain if 
these proteins have any essential post translational modifications which will affect 
their immunological reactivities. Therefore, we first chose E.coli to express our SARS 
structural proteins. 
Several attempts will be tried to increase the overall bioactive protein expressed 
in E. coli. Up to the moment, most of the recombinant proteins expressed in E. coli 
have been reported to be in the form of inclusion bodies for a large portion. Several 
SARS nonstructural (Cheng et al, 2005; Zheng et aL, 2005) or structural proteins 
(Zhao et al” 2005; Zhou et al” 2004) have been reported to be successfully expressed 
in E. coli as insoluble aggregates. The formation of inclusion bodies is mainly due to 
the overexpression of proteins in the cell lacking the required accessories for its 
folding to the native form (Mitraki et al” 1989). In general, protein expressed as 
inclusion bodies are solubilized by the use of high concentrations of urea (8M) or 
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guanidine hydrochloride (6M) along with reducing agents like 冷 - m e r c a p t o e t h a n o l . 
The soluble proteins are then refolded to their native state by dialyzing the proteins in 
buffers containing reducing and oxidizing agents (Rudolph et al., 1997). Despite 
several protocols available for protein solubilization and refolding, the overall 
recovery of bioactive proteins from inclusion bodies is often very low. To increase 
this recovery, low concentration of urea with alkaline condition could be tried. Under 
this condition, urea probably served as a reagent for the physical separation of the 
molecules by disrupting the hydrophobic interaction. Thus without actually 
denaturing the protein, the solubilized protein could persist native-like secondary 
structure during solubilization and the overall yield of purified bioactive proteins from 
inclusion bodies can be improved (Ashok et al., 2000). Another attempt to improve 
the yield of protein expressed in E. coli is by changing culture conditions, including 
expression temperature and time. 
We have engineered a His-tag fusion at the 5' end or 3'end of all recombinant 
proteins to facilitate the purification of these by using Immobilized Metal Affinity 
Chromatography (IMAC). Since only His-tag fusion proteins will bind to the 
chelating column and be eluted only during the elution process, other contaminating 
proteins can be discarded during the wash step. Other purification methods will be 
tried for further purification after IMAC. 
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2.2 Materials 
2.2.1 Reagents for bacterial culture 
2.2.1.1 Luria-Bertani (LB) medium 
It was prepared by dissolving 20g LB broth (USB, USA) in IL dHiO. The 
medium was autoclaved for 20 min at 121°0 and l.lkg/cm^ on liquid cycle before 
use. 
2.2.1.2 Ampicillin solution 
Ampicillin was purchased from USB (USA) and lOOmg/ml stock solution in 
dHaO was prepared. The stock solution was sterilized by filtration through a 0.2 // m 
pore size membrane filter. One ml aliquots were made and were stored at -20°C • 
2.2.1.3 Kanamycin solution 
Kanamycin was purchased from Amersham (UK) and lOOmg/ml stock solution 
in dH20 was prepared. The stock solution was sterilized by filtration through a 0.2 fi 
m pore size membrane filter. One ml aliquots were made and were stored at -20°C. 
2.2.1.4 LB ampicillin (LBA) and LB kanamycin (LBK) medium 
LB A is LB medium supplemented with ampicillin at 100//g/ml and LBK is 
supplemented with kanamycin at 50 ji g/ml. 
2.2.1.5 LB, LBA and LBK agar plates 
LB agar medium was prepared by the addition of agar (Sigma, USA) to LB 
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medium to 1.5% (w/v) before autoclaving. For LBA agar medium, ampicillin was 
supplemented at 100/zg/ml agar medium after autoclaving. For LBK agar medium, 
kanamycin was supplemented at 50 ji g/ml agar medium after autoclaving. 
Luke-warm agar medium was poured into 90mm disposable Petri dishes at 
�20ml/dish. The agar plates were allowed to set at room temperature and then stored 
at 4°C. Just before use, the agar plates were dried by placing them in a 37°C 
incubator for 2hr. 
2.2.1.6 Isopropylthio- /5 -D-galatoside (IPTG) 
IPTG stock solution was prepared as a 0.4M solution in dHzO. The solution was 
sterilized by filtration through a 0.2 // m pore size membrane filter. One ml aliquots 
were made and stocked at -20°C. 
2.2.1.7 Calcium-glycerol buffer 
It consisted of 60mM CaCl, lOmM Piperazine-A/;A^-bis[2-ethanesulfonic acid] 
(Pipes), 15% glycerol. The solution was sterilized by 0.2/zm pore size membrane 
filter. 
2.2.2 Reagents for agarose gel electrophoresis 
2.2.2.1 Tris-acetate-EDTA (TAE) electrophoresis buffer 
A 5Ox stock solution was prepared by dissolving 242g Tris base in 800ml d d H : � . 
Afterwards, 100ml 0.5M EDTA solution (pH8.0) and 57.1ml glacial acetic acid were 
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added. The solution was made up to IL with ddHsO. It was diluted 50-fold before use. 
2.2.2.2 DNA sample loading buffer 
A 6x buffer was prepared by mixing 0.25% (w/v) bromophenol blue, 0.25% (w/v) 
xylene cyanol FF and 40% (w/v) sucrose solution in sterile dHaO. The buffer was 
stored at 4°C. 
2.2.3 2‘-deoxyribonucleoside 5'-triphosphate (dNTP) mix for polymerase chain 
reaction (PCR) 
The ultrapure dNTP set was purchased from Amersham Biosciences (USA). Ten 
mM stock of dNTP was prepared by mixing 10/zl of each of the dATP, dTTP, dCTP, 
and dGDP with 60 jjl 1 of sterile dH20. The stock solution was stored at -20°C. 
2.2.4 Sonication buffer 
It was 50mM HEPES-NaOH (pH7.5) containing 0.5M NaCl, ImM PMSF, 1% 
(v/v) Triton-X 100 and 0.35 mg/ml lysozyme (Sigma, USA). 
2.2.5 Reagents for immobilized metal affinity chromatography (IMAC) purification 
2.2.5.1 Start buffer 
It was 20mM NasPO* with pH adjusted to 8.0 with IM NaOH and IM NaCl. The 
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buffer was filtered with 0.45 (i m filter before use. The solution was stored at 4�C. 
2.2.5.2 Washing buffer 
It was the start buffer with the addition of 20mM imidazole (USB, USA). 
2.2.5.3 Elution buffer 
It was the start buffer with the addition of lOOmM imidazole. 
2.2.6 Reagents for gel filtration chromatography 
2.2.6.1 Sample treated buffer 
Before running the gel filtration column, the sample was first treated with 6 M 
guanidine HCl. 
2.2.6.2 Running buffer 
The running buffer was composed of SOmM Tris, IM urea and 0.15M NaCl, pH 
8.0. 
2.2.7 Reagents for sodium dodecylsulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
2.2.7.1 Acrylamide/ Bis Solution 
The solution was purchased from Bio-Rad (USA). The concentration of the 
solution was 30% with the cross-linker ration 29:1. The solution was stored at 4°C. 
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2.2.7.2 Resolving gel buffer 
The buffer was 1.5M Tris-HCl dissolved in dHjO. The pH of the buffer was 
adjusted to 8.0 with IM NaOH. 
2.2.7.3 Stacking gel buffer 
The buffer was IM Tris-HCl dissolved in dHaO. The pH of the buffer was 
adjusted to 6.8 with IM NaOH. 
2.2.7.4 10% SDS solution 
The solution was prepared by dissolving lOg SDS in a final volume of lOOmL 
dHzO. 
2.2.7.5 10% Ammonium persulfate solution 
The solution was prepared by dissolving 0.5 g ammonium persulfate in a final 
volume of 5mL dHaO. The solution was stored at -20°C. 
2.2.7.6 Sample loading buffer 
A 6x working solution was prepared with 12% (w/v) SDS, 375mM Tris-HCl (pH 
6.8), 60% (v/v) glycerol and 0.01% (w/v) bromophenol blue. For reducing disulphide 
bonds of proteins, 5% (v/v) /3 -mercaptoethanol was added just before use. 
2.2.7.7 Tris-glycine electrophoresis buffer 
A 5x stock solution was prepared by dissolving 15.1 g Tris base and 94 g glycine 
in 900mL dHaO. Fifty milliliters 10% (w/v) SDS solution was added, and the volume 
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was adjusted to IL with dHzO. The stock solution was diluted 5-fold before use. 
2.2.7.8 SDS-PAGE staining solution 
It was prepared by dissolving 0.25 g Connmassie Brilliant Blue R-250 (Sigma, 
USA) in 90mL 1:1 (v/v) ethanol: dHzO mixture and lOmL glacial acetic acid. 
2.2.7.9 SDS-PAGE destaining solution 
It was prepared by mixing 250mL ethanol with 80mL glacial acetic acid and 
made up to IL with dHaO. 
2.2.8 Reagents for Western Blotting 
2.2.8.1 Bjerrum and Schafer-Nielsen transfer buffer 
It was prepared by dissolving 5.82 g Tris and 2.93 g glycine in a minimal volume 
of ddHjO. 3.75mL 10% (w/v) SDS solution and 200mL analytical grade absolute 
methanol were then added. The final volume was made up to IL with ddHzO. The pH 
of the buffer ranged from 9.0 to 9.4. 
2.2.8.2 Wash buffer (PBST) 
It was PBS containing 0.1% (v/v) Tween 20 (USB, USA). 
2.2.8.3 Blocking solution 
It was PBST containing 5% (w/v) non-fat dried milk powder. 
2.2.8.4 Alkaline phosphatase (AP) substrate buffer 
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It was a buffer of O.IM Tris base, O.IM NaCl and 5mM MgCl2. The pH of the 
buffer was adjusted to 9.5 with IM HCl. 
2.2.8.5 AP substrate solution 
Nitro blue tetrazolium (NBT) solution was prepared by dissolving lOmg NBT 
(Sigma, USA) in ImL ddHsO. 5-Bromo-4-chloro-3-indolyl phosphate (BCIP) 
solution was prepared by dissolving 50mg BCIP (Sigma, USA) in ImL ddHaO. Both 
solutions were stored in a dark bottle and kept at -20°C. Just before use, 200 ji L NBT 
solution and 25 // L BCIP solution were added to lOmL AP substrate buffer (for each 7 
X 5 cm^ membrane) to constitute the AP substrate solution. 
2.3 Methods 
2.3.1 General techniques in molecular cloning 
2.3.1.1 Preparation of Escherichia coli competent cells 
An appropriate E. coli strain was streaked from frozen glycerol stock onto a LB 
agar plate the day before the preparation of competent E. coli cells. The streaked plate 
was incubated at 37�C for 16-18 hours. A single colony of 2-3mm in diameter was 
picked and inoculated into 5ml LB medium and was then grown overnight at 37°C in 
a shaking incubator at 250 rpm. Two ml of the overnight culture was inoculated in 
200ml LB medium and incubated at 37°C with shaking at 250 rpm until OD600 
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reached 0.4. Cells were chilled on ice for 5 min and then collected by centrifugation at 
6000 rpm for 10 min at 4°C. Cell pellet was then gently resuspended in 20ml ice-cold 
sterile filtered Calcium-glycerol buffer. Cells were pelleted by centrifugation at 6000 
rpm for 10 min at 4°C，followed by gently resuspending in 20ml ice-cold 
Calcium-glycerol buffer and incubating on ice for 30 min. Cells were collected by 
centrifugation at 6000 rpm for 10 min at 4°C and then resuspended in 5ml of 
Calcium-glycerol buffer. Competent cells were dispensed into 100 // 1 aliquots, 
snapped freeze in liquid nitrogen, and stored at -70°C until use. 
2.3.1.2 Transformation of DNA vectors in E. coli (heat-shock method) 
E. coli strain DH5 a was used for transformation of DNA vectors. Frozen 
competent cells were thawn on ice until the suspension just liquefied. Plasmid DNA 
or ligation product to be transformed was added to each aliquots of competent cells in 
a volume of less than 30 fi 1. The tubes were finger-mixed gently and placed on ice for 
45 min. Heat-shock transformation was performed by placing the tubes into a 42°C 
water bath for 2 min and returning them immediately on ice for 5 min. Nine hundred 
II1 LB medium was added to each tube. The transformed E. coli were recovered by 
incubating at 37°C for 45 min with shaking at 250 rpm. The recovered cells were 
then spread onto LB A agar plates and incubated at 37°C for 16-18 hr. Bacterial 
colonies formed were picked and screened for the presence of recombinant plasmid 
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by PCR and restriction mapping analysis. 
2.3.1.3 Small scale plasmid preparation 
In a small scale plasmid preparation, discrete colonies of plasmid-bearing cells 
were grown in 5ml of LBA medium overnight at 37°C with shaking at 250 rpm. The 
overnight bacterial culture was harvested by spinning for 1 min in a brench-top 
microcentrifuge at 14000 rpm. The plasmids were prepared by using the Wizard® 
SV Minipreps DNA Purification System (Promega, USA) according to the 
manufacture's instruction. 
2.3.1.4 Primer preparation 
All primers were synthesized by Invitrogen (USA). The primers were 
reconstituted to a concentrating lOmM and stored in sterile dH^O. A ImM working 
solution was prepared by mixing 10//1 of lOmM stock solution with 90//I sterile 
dH20. All the solutions were stored at -20°C. 
2.3.1.5 PCR 
PCR was performed by mixing 1/zl of DNA template (about 20ng), lul of 
forward and reverse primer (lOpmol), 1 of dNTP stock solution (lOpmol), 5//I of 
lOx PCR buffer (Expand HF buffer with 15mM MgCl�）and lU of DNA polymerase 
(Expand High Fidelity PCR System, Roche, USA). The reaction volume was adjusted 
to 50/zl by sterile dHzO. The PCR reaction was performed in a Gene Amp PCR 
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System (Applied Biosystems, USA) following conditions to be specified in each 
experiment. 
2.3.2 PGR amplification of the Si-400，S401-1000 
The genome sequence used for amplifying Si_400 and S401-1000 in this study was 
based on the SARS-CoV complete cDNA genome sequence which is sequenced by 
CUHK with the code of CUHK-SulO (http://www.ncbi.nlm.nih.gov/entrez： accession 
number: AY282752). PGR primers containing restriction sites, BamH I and Not I, and 
coding regions of Smoo and S401-1000 (full sequences: Appendix 1) respectively were 
synthesized by Invitrogen (USA). 
Si_4oo: BamHI forward primer: 5'GCGGATCCTTTATTTTCTTATTATTTCTTACT 3， 
NotI reverse primer: 5,GCGCGGCCGCTCCTGGCGCTATTTGTCTTACATC3， 
S401-1000: BamH I forward primer: 
5'GCGGArCCATGCACCACCACCACCACCACCAAACTGGTGTTATTGCTGAT 
TAT3, 
Not I reverse primer: 
5'GCGCGGCCGCTCACCTGATTTCAGCAGCCCTGATTAG3 ’ 
(The corresponding restriction enzyme recognition sites are underlined) 
PCR amplification was performed according to the following cycle condition: 
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Step 1: 941： 5min 
Step 2:94°C 36 sec 
55°C 45 sec ^ 35 cycles 
72°C 3 min � 
Step 3: 72°C 7 min 
The PCR products were analyzed on a TAE agarose gel (Figure 2.1) which 
shown bands of approximately 1200bp and ISOObp respectively. These PCR products 
were expected to contain BamH I and Not I restriction sites at the 5' and 3’ ends, 
respectively. 
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3000 bp 
1200 bp ^ — — 1 2 0 0 bp 
3 4 
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2000 bp 1800 bp 
Figure 2.1 P C R products of SMOO and S401-1000. Lane 1 and 3: DNA marker. Lane 2: 
Si-400 PCR product with BamH I and Not I restriction sites. Lane 3: S401-1000 PCR 
product with BamH I and Not I restriction sites. 
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2.3.3 Construction of clone pET-Si-400 and PET-S401-1000 
The PCR amplified Si-400 and S401-1000 gene was subjected to gene clean by using 
Concert rapid gel extraction system (GibcoBRL, USA). The purified PCR fragments 
were then digested by restriction enzyme: BamH I and Not I (Amersham Biosciences, 
USA). About 500ng of PCR fragment was mixed with 1 /zl of the One-Phor-All 
buffer (Pharmacia Biotech, USA) in 8/zl final volume. One ji 1 of both restriction 
enzymes (lOU) were added into the reaction mixture which was then incubated at 37 
�C for about 3 hours. 
The expression vector used here was pET32 (a) (Figure 2.2) which was 
purchased from Novagen (USA). The vector was designed for cloning and high-level 
expression of peptide sequences fused to the 109 amino acid bacterial thioredoxin 
protein (Trx-Tag A cleavable His-Tag fused at 5' end of the cloning sites is 
available for producing a hexahistidine peptide in the recombinant protein to facilitate 
purification (Figure 2.3). 
Ten jji 1 of pET32 (a) vector (about 500ng) obtained from a miniprep reaction 
was cut by Bam HI and Not I for 3 hours. Gene clean was performed to purify the cut 
inserts and the digested vector. Six//I of inserts, Si-400 and S401-1000 ( each about 
300ng)，and 2 # 1 of vector (about lOOng) were mixed with 1/zlof lOx ligation buffer 
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(660mM Tris-HCl, pH 7.6，66mM MgCl2, lOOmM DTT, 660 fi M ATP) and 1 /z 1 of 
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Figure 2.2 Schematic representation of pET32 (a) expression vector (Adopted from 
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the website http://www.novagen.com) 
6x His T7 promoter trx A S400 /SIOOO sequence 




His-tag S400/SIOOO - l O k D a 
Figure 2.3 Schematic diagram of the vector construct of the S 1.400 or S 4 0 1 - 1 0 0 0 fusion 
protein. A thioredoxin protein and a his-tag were fused to the recombinant Smoo / 
S 4 0 1 - 1 0 0 0 protein at the N terminal. 
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lU T4DNA ligase (USB, USA) respectively. Ligation was performed at 16°C for 16 
hr and the ligation mixture was then used to transform DH5 a . 
After PCR and restriction mapping analysis, colonies of DH5 a cells bearing 
the recombinant expression vector were selected for miniprep of the plasmid. The 
purified samples were sequenced (TechDragon, Hong Kong). After confirmation of 
correct sequence, 2 / i l of the tested plasmid (about lOOng) was transformed into 
Origami (DE3) expression cells (Novagen, USA). 
2.3.4 Construction of clone pAC-N 
The full-length N protein has been cloned into expression vector pAC28 which 
was modified from pET28 (a) (Novagen, USA) (Figure 2.4). The construct was made 
in the lab of Prof. Shannon Au (Biochemistry, CUHK) and we are grateful for this gift. 
The construct was transformed into competent cell BL21 (Invitrogen, USA) in our lab 
and the size of the recombinant N protein was predicted to be around 45kDa with a 
His tag fusion at the 5，terminal. 
2.3.5 Expression 
2.3.5.1 Expression of recombinant proteins rSi-400(E) and rS4oi-1000(E) 
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Figure 2.4 Schematic representation of pET28 (a) expression vector (Adopted from 
the website http ://www.novagen.com) 
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overnight in 20ml LB A medium at 37�Cwith shaking at 250rpm. Five-hundred ml of 
LBA medium was inoculated with the overnight culture and allowed to grow for 
about 3hr at 37°C with shaking at 250rpm in order to reach an O.D.600 at 0.6-0.8. 
IPTG was added to the culture to a final concentration of ImM to induce protein 
expression. After 3hr, the culture was harvested by centrifuging at 6000rpm for 1 Omin. 
The bacterial cell pellets were stored at -20°C. 
2.3.5.2 Expression of recombinant protein rN(E) 
The method of PAC-N expression was the same as rS 1.400(E) or rS4oi-iooo(E) 
except that the culture medium was replaced by LBK. 
2.3.6 Inclusion bodies preparation 
The bacterial cell pellet was first resuspended in sonication buffer and then 
sonicated by cycles of 30s followed by cooling until the cell suspension became 
translucent. After centrifugation at 13000 rpm for 20min, the pellet was washed three 
times with 50mM Tris-HCl (pH 8.0) containing ImM EDTA and l%(v/v) 
Triton-X 100. Afterwards, with a final wash with 50mM Tris-HCl (pH 8.0) containing 
ImM EDTA and 0.5M Guanidine HCl, the inclusion bodies obtained were stored at 
-20°C or used for solubilization at 4°C immediately. 
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2.3.7 Inclusion bodies solubilization using urea 
Ten ml of lOOmM Tris-Base, pH 12.5, with 2M urea was added to the inclusion 
bodies obtained from 500ml bacterial culture. The sample was incubated at 4°C 
overnight with gently shaking. The sample was centrifuged at 13000 rpm for 20min at 
4°C. The supernatant containing the solubilized protein was harvested. 
2.3.8 Protein refolding by rapid dilution and dialysis 
The protein sample was adjusted to a final concentration of Img/ml with 25mM 
Tris-Base. The solubilized protein was quickly diluted 4x by dispensing the sample 
into cold (4°C) 25mM Tris-Base buffer. Before dialysis, the pH of the protein solution 
was adjusted by concentrated HCl from 12.5 to 7.8-8.0. Then the solubilized protein 
were refolded by dialysis with 25mM Tris-Base or 20mM NasPCU, pH 8.0，at 4°C 
overnight to remove the remaining urea. 
2.3.9 Purification of recombinant protein by nickel ion chelating Sepharose fast flow 
column (IMAC) 
The nickel ion chelating column was used first in this project. The His-tagged 
proteins can bind specifically to the column. Other unrelated proteins were removed 
in the washing steps. 
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2.3.9.1 Preparation of chelating Sepharose fast flow column 
The nickel ion chelating sepharose applied in this study is Ni-NTA 
(Nitrilotriacetic acid) developed by QIAGEN, Hilden German. Since Ni-NTA has 4 
metal-chelating sites compared with Ni-IDA (iminodiacetic acid) which has only 3 
metal-chelating sites (Figure 2.5), it is thus a stronger binding resin. The unique NTA 
matrices can bind 6xHis-tagged proteins more tightly than IDA matrices, allowing the 
purification of proteins from less than 1% of the total protein preparation to more than 
95% homogeneity in just one step (Janknecht et al” 1991). 
The Ni-NTA agarose was supplied in 20% ethanol. To prepare the gel for 
chromatography it was resuspended by gentle rocking of the container and transferred 
into a 50ml Falcon tube. The gel was washed with 3 bed-volumes of dHaO and then 
equilibrated in 3 bed-volumes of Start buffer. 
2.3.9.2 Purification of recombinant protein 
Twenty ml of solubilized inclusion body (around 0.5mg/ml) was dialyzed against 
2L of start buffer overnight at 4°C. The dialyzed sample was mixed with 10ml 
Ni-NTA gel in a 50ml Falcon tube. The mixture was incubated at 4°C for Ihr with 
end-over-end rotation. Afterwards, the slurry was packed into a 10mm x 100mm glass 
Econo-Column chromatography column (Bio-Rad, USA). The flow through was 
collected and the column was washed with 3 bed-volumes of start buffer followed by 
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Figure 2.5 (A) Comparison of the interaction of different metal chelate matrices with 
nickel ions. (B) Interaction between neighboring residues in the 6xHis tag and 
Ni-NTA matrix. 
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10 bed-volumes of wash buffer. The recombinant protein was eluted by 5 
bed-volumes of elution buffer. Al l the samples were assayed by SDS-PAGE and 
western blotting. 
2.3.9.3 Gel regeneration 
The column was regenerated by washing with 3 bed-volumes of dHzO followed 
by 4 bed-volumes of 0.5M NaOH to remove non-specific bound proteins. After 
washing with 5 bed-volumes of dHaO, the gel was equilibrated with 3 bed-volumes of 
20% ethanol and then transferred into a 50ml Falcon tube for storage at 4°C. 
2.3.10 Gel filtration chromatography for further purification 
For further purification, gel filtration was used to separate proteins based on size. 
The larger proteins which cannot be trapped inside the gel matrix wil l be eluted earlier. 
The smaller proteins which can permeate inside the matrix to various degrees wi l l be 
eluted later. 
The column we used was Superose 12 with a fractionation range of 1000 to 
300000 MW. Fractions containing different sizes of proteins were collected 
automatically by using a liquid chromatography controller (Pharmacia, USA). 
2.3.11 Bradford assay for the protein concentration analysis 
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This protein assay kit was recommended by Bio-Rad. First, a set of protein 
standard was made by BAS stock (lOmg/ml) diluted with distilled water and ended up 
with the series concentrations at 0.1 mg/ml, 0.2mg/ml, 0.4mg/ml, 0.6mg/ml, 0.8mg/ml 
and 1 mg/ml. Then 4 / i l of sample was mixed with 5 fold diluted Bradford solution 
(200 (11). The mixture was thus incubated at room temperature for 15mins. Finally, 
the absorbance of the sample at ODses was examined by Bio-Rad Microplate 
Manager. 
2.3.12 Protein analysis 
2.3.12.1 Protein separation by SDS-PAGE 
SDS-PAGE was carried out according to Laemmli (1970). Resolving gel with 
different concentration of acrylamide and stacking gel (Table 2.1) were prepared and 
casted in the Mini-PROTEIN® I I electrophoresis cell (Bio-Rad, USA). Each sample 
was mixed with 1/6 volume of 6x sample loading buffer and heated at 99�C for 5 min. 
The samples were then loaded and the gel ran at 30mA/gel. 
2.3.12.2 Coomassie Brilliant Blue R-250 staining of SDS gels 
Gels were staining in SDS-PAGE staining solution at room temperature 
overnight with gentle shaking. The gels were then destained in destaining solution at 
55 °C with gentle shaking until the background was completely removed. After 
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Table 2.1 Preparation of resolving and stacking gel 
Resolving gel 
12.5% 15% 
dHaO 3.13ml 2.3ml 
Acrylamide/Bis solution 4.17ml 5ml 
Resolving gel buffer 2.5ml 2.5ml 
10% SDS 100/zl 100//I 
10% ammonium persulfate 100/zl 100//I 
TEMED ^ ^ 
Total volume 10ml 10ml 
Stacking gel 
dHzO 2.73ml 
Acrylamide/Bis solution 0.67ml 
Resolving gel buffer 0.5ml 
10% SDS 40/zl 
10% ammonium persulfate 40 //1 
TEMED ^ 
Total volume 4ml 
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rinsing with tap water, the gels were dried under vacuum. 
2.3.12.3 Protein transfer using Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, 
USA) 
The resolving gel was equilibrated in chilled Bjerrum and Schafer-Nielsen 
transfer buffer for 15 min. A piece of 0.2 (i m pore-size PVDF membrane (Bio-Rad, 
USA) cut to the size of the gel was activated in reagent grade methanol and then 
equilibrated in the transfer buffer for 15 min. Four filter papers cut to the size of the 
gel were also soaked in the transfer buffer. The transfer cell was set up as illustrated in 
Figure 2.6. Proteins were transferred from the gel to the PVDF membrane at 15V for 
45 min. After the transfer, the membrane was ready for Western blotting. The 
efficiency of protein transfer was checked by staining the transferred gel with 
Coomassie Brilliant Blue R-250. 
2.3.12.4 Western blotting 
Each membrane was blocked in lOmL blocking buffer at room temperature for 
30 min. Ten /zg of first monoclonal antibody was added. Probing of antigen was 
carried out at room temperature for one hour or at 4°C overnight with gentle shaking. 
The membrane was then washed three times (5 min each) in 15mL pre-chilled wash 
buffer. Afterwards, lOmL blocking buffer was added with 2 / i L EIA-Grade affinity 
purified goat-anti-mouse IgG (H+L) AP conjugate (Bio-Rad, USA) (5000 fold 
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Figure 2.6 An exploded view of the Trans-Blot SD cell. 1: safety lid; 2: cathode 
assembly with latches; 3: filter papers x 2; 4: resolving gel; 5: PVDF membrane; 6: 
filter papers x 2; 7: spring-loaded anode platform; 8: power cables; 9: base. (Adopted 
from the website: Bio-Rad http://www.biorad.com) 
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dilution). The membrane was incubated at room temperature with gentle shaking for 
one hour and it was washed again with wash buffer as mentioned before. Finally, 
1 OmL AP substrate solution was added. Color development was carried out in the dark 
at room temperature for 20 min and was stopped by flushing the membrane under tap 
water for 2 min. The membrane was then air-dried and kept away from strong light. 
2.4 Results 
2.4.1 SDS-PAGE analysis of the expressed proteins 
The expression was performed according to Section 2.3.5. After IPTG induction 
for 3hr, 5ml of the bacterial culture was collected by centrifugation at 14000 rpm for 
Imin using a bench-top microcentrifuge. The pellet was resuspended in 5 0 0 P B S 
and was then disrupted by sonication. The disrupted cell suspension was spun down at 
14000 rpm for 1 min. The supernatant was collected and was designated as the 
soluble fraction of the bacterial cell lysate. The pellet was resuspended in 500 {i 1 PBS 
and was labeled as the insoluble fraction. Both these soluble and insoluble fractions 
were ready for SDS-PAGE analysis. As shown in the Figure 2.7，there were several 
protein bands shown up in the SDS-PAGE analysis. However, when compared with 
the soluble fractions, our target protein bands with the predicted molecular 
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Figure 2.7 SDS-PAGE analysis on expression of rSi-400(E) (A), rS4oi-iooo(E) (B), and 
rN(E) (C) in E. coli. Lane 1, 4，7: Protein marker; Lane 2, 5, 8: soluble fraction of the 
bacterial cell lysate; Lane 3，6’ 9: insoluble fraction of the bacterial cell lysate. 
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weight (rSi_4。。(E) around 55kDa, rS4oi-iooo(E) around 80kDa and rN(E) around 45kDa) 
appeared to be more intensely staining than other unrelated proteins. Al l these 
candidate bands were associated with the insoluble fraction without any similar bands 
in the corresponding soluble fractions. The present result indicated that our target 
proteins were probably expressed as inclusion bodies. 
2.4.2 Western blot analysis of the bacterial cell lysate 
In order to verify whether the intense bands in the SDS-PAGE gel were the 
fusion proteins we want to express, western blot analysis was performed on both 
insoluble and solube fractions. Since all of these target proteins are His-tag fusion 
proteins, Anti-His antibody (Amersham, USA) can be used for detection. As shown in 
the Figure 2.8, in the insoluble fraction there were several protein bands reacting with 
Anti-His antibody instead of only one band. However, we still found that the most 
intense bands could be indicated at the same positions as predicted. The soluble 
fraction did not show any bands reacting with the Anti-His antibody except for the 
case of rS4oi-iooo(E). We believed that the band shown in the soluble fraction was the 
excessive protein from the neighboring lane. This experiment further confirmed that 
our target proteins were probably expressed in the insoluble fraction. 
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Figure 2.8 Western blot analysis of expression of rSi_400(E) (A), rS4oi-iooo(E) (B), and 
rN(E) (C) probe with Anti-His antibody. Lane 1, 4, 7: Protein marker. Lane 2，5，9: 
soluble fraction of bacterial cell lysate. Lane 3，6，8: insoluble fraction of bacterial cell 
lysate. 
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2.4.3 Protein purification by IMAC 
After solubilization and refolding of the recombinant proteins by methods 
mentioned in Section 2.3.7 and 2.3.8，the sample was applied onto a Ni-NTA column 
according to procedures described in Section 2.3.9.2. Different fractions were assayed 
by SDS-PAGE (Figure 2.9). As shown in the SDS-PAGE, after IMAC purification, 
both rS 1400(E) and rN(E) can be purified to 90% purity. However, the purity of 
rS4oi-1000(E) was much lower. Therefore, the fraction of rS4oi-iooo(E) was further 
purified by gel filtration. In the case of rSi-400(E) (Figure 2.9 A) and rS4o 1-1000(E) 
(Figure 2.9 B), no protein bands could be detected in the original sample (lane 1 and 
8). This was probably due to low concentration of protein resulting from refolding 
mixture. 
2.4.4 Purification of 18401-1000(E) by gel filtration 
The elute fraction of rS4oi-iooo(E) from M A C was further fractionated by gel 
filtration chromatography. Different fractions were collected according to the time of 
elution (Figure 2.10) and assayed by SDS-PAGE and western blotting. As shown in 
the Figure 2.11, the purity of rS4o 1-1000(E) was improved significantly compared with 
the original material and a purity of over 90% was achieved by vision impression. 
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Figure 2.9 IMAC purification of recombinant protein rS 1.400(E) (A), 18401-1000(E) (B) 
and rN(E) (C). Different fractions obtained from the purification process were assayed 
by SDS-PAGE. Lane 7, 15: Protein marker; Lane 1, 8, 16: Samples before passing 
through the colume; Lane: 2，3，4，9，10，11，17: column wash fractions; Lane 5, 6，12， 
13, 14, 18, 19, 20,21: elute fractions. 
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Figure 2.10 OD280 purification profile of partially purified PET-SI 800 by Superose 12 
gel filtration chromatography. The elution profile is shown and fractions from 
different time slots were collected. 1，2, 3 and 4 indicated fractions collected and 
analyzed. 
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Figure 2.11 SDS-PAGE (A) and corresponding western blotting (B) analysis of 
rS4oi-1000(E) further purified by gel filtration chromatography. Lane 1: protein marker; 
Lane 2: original elute fraction from IMAC; Lane 3, 4, 5 and 6: peak 1，2，3 and 4 from 
gel filtration elute fractions. 
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2.4.5 Determination of production yield of recombinant fusion proteins 
After IMAC, the amount of recombinant proteins purified was assayed by 
Bradford assay according to Section 2.3.11. 3.36mg of rSi^oo(E), 6.26mg of 
rS4oi-iooo(E) and 5.56mg of rN(E) were obtained respectively from 200ml culture 
medium. In the case of rS4oi-iooo(E)，2.26mg rS4oi-iooo(E) after the gel filtration was 
finally obtained. According to this interpretation, the total yield of rSi-400(E), 
rS4oi-1000(E) and rN(E) was 16.8mg/L, 11.3mg/L and 27.8mg/L respectively. 
2.5 Discussion 
2.5.1 Expression vector selected for rSi-400(E) and rS4oi-iooo(E) expression 
There are several reasons for choosing pET32 (a) as the expression vector for 
rSi-400(E) and rS4oi-iooo(E) expression. First, it is the most suitable vector for protein 
expression in Origami (DE3) as recommended by the manufacturer. Second, the 
vector contains a fusion fragment of thioredoxin which can stabilize the fusion protein 
as well as increase production yield (LaVallie et al.’ 1993). Third, the vector contains 
a His-tag fusion which facilitates the purification of the recombinant protein by 
IMAC. 
2.5.2 Protein expression in E.coli 
In this part of our work, the target proteins were expressed in the form of 
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inclusion bodies. Recombinant proteins expressed in the form of inclusion bodies 
have several advantages. They always have high production yield. Protein aggregates 
in inclusion bodies are resistance to proteolytic degradation. Furthermore, the 
formation of inclusion bodies facilitates the easy isolation of the expressed proteins 
from a large amount of contaminating soluble bacterial proteins. However, the most 
critical problem in handling inclusion bodies is how to refold the protein properly 
after solubilization in which strong denaturing agents are used. The failure of gaining 
back the protein's native structure could lead to a low recovery of the active product. 
Therefore, we decided to use a modified solubilization method to solubilize the 
inclusion bodies under lower concentration of urea in order to preserve the secondary 
structure as well as to reduce the loss of active proteins during the recovery step. In 
our pervious work on another protein, we have obtained nearly 48mg/L properly 
folded protein using a similar solubilization process (Leung 2002). However, the 
production yield of rSi-400(E), rS4oi-iooo(E) and rN(E) was still less than what we had 
expected. We found that the difference between the final protein yields was mainly 
due to the level of protein expression. As indicated in Figure 2.7, the target protein 
bands of all three proteins were only slightly denser than other contaminating proteins. 
We have made several attempts to increase the level of protein expression. First, since 
the overall level of expression and the amount of protein formed in inclusion bodies 
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were found to increase with time after induction, we increased the time of induction 
from 4hr to 5hr and overnight. Second, as the level of expression and solubility of the 
recombinant protein may vary by the amount of IPTG used for induction (Fang et al., 
2004)，the effect of different IPTG concentrations was tested. Unfortunately, as 
indicated in the Figure 2.12，all the conditions we have tried did not show any 
improvements. 
To enhance the expression level of these recombinant proteins, several methods 
may be tried in the future. First, these foreign genes can be modified with an 
optimized E.coli codons. The growth of cells transformed by plasmids with codon 
optimization was reported to be significantly faster than that of the cells without 
codon optimization (Zhou et al., 2004). Thus, codon optimization significantly 
increases the yield of protein in the E.coli expression system. Moreover, since 
bacterial culture in shake flask has limitation in scaled up, fermentation for large-scale 
production of these proteins may be tried in the future. 
2.5.3 Purification processes 
In the purification of rSMoo(E), rS4oi-iooo(E) and rN(E), we first used IMAC to 
purify these His-tagged recombinant proteins. Both rS 1.400(E) and rN(E) could be 
purified to high purity after the chromatographic step. However, using the same 
approach, the purity of rS4oi-iooo(E) was relatively low. Different washing and elution 
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conditions by changing pH and imidazole concentration may be tried to improve the 
results from IMAC. Unfortunately, we were not able to establish an effective 
purification scheme using IMAC alone. Therefore we chose a combination with other 
chromatography for further purification of rS4oi-iooo(E). Affinity chromatography, gel 
filtration chromatography and ion-exchange chromatography are the common and 
well-developed purification methods. Proteins interact biospecifically with Blue 
Sepharose can be purified by affinity chromatography. It depends on the protein 
structural similarity with cofactors. Ion-exchange chromatography can be used to 
separate proteins with different charge properties. It is a very sensitive method and 
capable of separating species with very minor differences in properties, e.g. two 
proteins differing by only one charged amino acid. The development of gel filtration 
chromatography introduced an extremely valuable method by which molecules can be 
separated from each other on the basis of their sizes. In our case, the differences of 
protein structure, charge property and hydrophobicity between the major band of 
rS4oi-1000(E) and contaminating bands cannot be differentiated by SDS-PAGE analysis. 
Since the rS4oi-iooo(E) has a molecular weight larger than the contaminating ones, gel 
filtration chromatography was our logical choice for further purification. By using this 
chromatography, we were able to purify rS4oi-iooo(E) protein to over 90%. 
Nevertheless, as the major band was also present in the second elution fraction 
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together with other contaminating bands. The cutting of the appropriate fractions has 
cost the loss of our protein during this further purification step. 
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Figure 2.12 SDS-PAGE analysis of rS4oi-iooo(E) expression. The cell lysates were 
collected from 4hr (lane 2，3，4)，5hr (lane 5, 6’ 7) and overnight (lane 8，9, 10) culture 
respectively. Each set of cell lysates contained respectively the uninduced and induced 
fractions which were induced by 0.5mM IPTG and ImM IPTG Lane 1: protein 
marker. 
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Chapter 3 Baculovirus expression and purification of rS4oi.iooo(ACN) and 
rN(BMN) protein 
3.1 Introduction 
As mentioned in Section 1.8.4，baculovirus expression system has been 
successfully employed to express biologically active recombinant proteins for 
pharmaceutical use. Although the modified solubilization method in Chapter 2 has 
enabled us to refold the recombinant proteins properly, we are not sure whether the 
post-translational modifications would affect the immunoreactivities of these proteins. 
Recombinant BmNPV or AcNPV which carries S401-1000 and N cDNA were 
constructed to evaluate this effect. However, we did not choose to express S1-400 
protein here. From our preliminary results, we found that S 1.400 had very weak ability 
to elicit immunoresponse against SARS-CoV. As shown in western blotting (Figure 
3.1)，rSi-400(E) cannot react with Hypo-IgG which was a highly concentrated human 
IgG fraction purified from SARS recovering patients. In contrast, the reaction 
between rN(E) and Hypo-IgG was very strong and specific. In the case of ELISA, 
rS 1.400(E) showed roughly the same response to SARS patients' sera and normal 
human serum (data not shown). 
We have tried to use both the baculovirus vectors, AcNPV and BmNPV, to 
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express our recombinant proteins in the present study. AcNPV and BmNPV belong to 
the same genera, but have highly specific hosts. For BmNPV, the silkworm is the 
natural host. The large-scale production of recombinant protein can be simply 
achieved by infecting silkworm (Bombyx mori) larvae. In the case of AcNPV, the 
natural host is the fall armyworm {Spodoptera frugiperdd). The host cells such as Sf9 
or Sf21 can only be grown by cell culture and scale up production of the protein is 
also possible by fermentation. However, for the generation of AcNPV, the more 
simple method of the Bac-to-Bac® Baculovims Expression System (Invitrogen) was 
used. This is an efficient site-specific transposition system developed to generate 
recombinant AcNPV baculovims. The process of AcNPV baculovims purification in 
this case was simplified compared with the standard protocol used for BmNPV. Both 
recombinant proteins expressed in this study were designed to possess a His-tag 
fusion for purification by IMAC and detection by anti-His antibody. The purity and 
yield of these proteins wil l also be presented in this Chapter. 
62 
Baculovirus expression and purification 
KDa 1 2 3 1 2 3 
114 — 
88 » . ••-•i.： 
51 — i d ^ S i y i i ^ ' i . “ 
36 ••！^二：^ ；^：^-^  
29 
22 一 I 
(A) (B) 
Figure 3.1 SDS-PAGE analysis (A) and western blotting (B) analysis of rSi_4oo(E) and 
rN(E). Lane 1: protein marker. Lane 2: rSi-400(E)- Lane 3: rN(E). In western blotting 
analysis, rSi •400(E) and rN(E) were reacted against hypo-IgG which was purified from 
recovering SARS patients. 
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3.2 Materials 
3.2.1 Reagents for insect cell culture and virus work 
3.2.1.1 Grace's insect cell culture medium, clean medium 
It was purchased from GibcoBRL (Grand Island, N. Y.) in liquid form in a 
package size of 500mL/bottle. The medium was supplemented with 500mg/L CaCl2, 
2800mg/L KCl, 3330mg/L lactalbumin hydrolysate, 3330mg/L yeastolate and 
L-glutamine. The medium was stored at 4°C. 
3.2.1.2 Fetal bovine serum (FBS) 
It was purchased from GibcoBRL (Grand Island, N. Y.) in a package size of 
500mL/bottle. Just before use, the serum was heat-inactivated (HIFBS) at 56°C for 
30 min. Aliquots of 20mL were prepared and stored at -20°C. 
3.2.1.3 Antibiotic-antimycotic (lOOOX) 
It was also purchased from GibcoBRL (Grand Island, N. Y.) in liquid form in a 
package size of lOOmL/bottle. It contained 10000 units of penicillin G, 10000/zg 
streptomycin sulphate and 2500 {i g amphotericin B (Fungazone®) in 0.85% saline. 
Five mL aliquots of this antibiotic-antimycotic (PSF) were made and stored at -20°C 
before use. 
3.2.1.4 Complete insect cell medium 
It was prepared by supplementing Grace's insect cell culture medium with 1% 
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(v/v) PSF and 10% (v/v) HIFBS. 
3.2.1.5 Infection medium 
It was prepared by supplementing Grace's insect cell culture medium with 1% 
(v/v) PSF. 
3.2.1.6 Recovery medium 
It was prepared by supplementing Grace's insect cell culture medium with 1% 
(v/v) PSF and 20% (v/v) HIFBS. 
3.2.1.7 Agarose solution 
A 2.5% (w/v) low temperature, low EEO sulphate content SeaKem® LE agarose 
solution (FMC® BioProducts, Santa Rosa, CA) was first prepared in ddHaO and 
autoclaved. It was melted in a microwave oven before use. 
3.2.1.8 Agarose overlay medium 
The melted agarose solution and the complete insect cell culture medium were 
separately warmed in a 50°C water bath. Just before overlaying onto infected cells, 
ImL of the agarose solution and 3mL of the complete insect cell culture medium were 
mixed thoroughly. 
3.2.1.9 Occlusion body lysis buffer 
It consisted of 0.1 M NaCOs and 0.05M NaCl. It was autoclaved before use. 
3.2.1.10 DTT solution 
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A 250mM stock solution of dithiothreitol (DTT) was prepared by dissolving 
0.7725g DTT in 20mL O.OIM sodium acetate solution, pH5.5. The DTT solution was 
sterilized by 0.2 j i m pore-size membrane filtration. One-milliliter aliquots were 
prepared and kept at -20°C. 
3.3 Methods 
3.3.1 PCR amplification of N and cloning of S401-1000，N genes into the transfer vector 
pVL1393 
The PCR product of N gene, which is around 1200bp, was amplified from the 
construct pAC-N with the following primers. 
N: Bam HI forward primer: 
5'GCGa^a:CCATGCACCACCACCACCACCACTCATCAGGTTCTGATAATGGA 
CCCCAATCA3' 
Not I reverse primer: 
5'GCGCGGCC^TCAGTGGTGGTGGTGGTGGTGACCTGATGATTATGCCTGA 
GTTGAATCAGC3' 
(The corresponding restriction enzyme recognition sites are underlined) 
PCR amplification was done according to the following cycle condition: 
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Step 1: 94°C 5 min 
Step 2:94°C 36 sec 
55°C 45 sec ^ 35 cycles 
72°C 3 min 」 
Step 3: 72°C 7 min 
After PCR amplification, N gene product contained a Bam HI and Not I 
restriction site at 5，end and 3，end, respectively. 
pVL1393 is a baculovirus transfer vector which can be propagated in E.coli. 
Upon cotransfection with baculovirus DNA, the cloned gene can undergo 
homologous recombination resulting in a recombinant viral genome. The cloned gene 
after insertion is then driven by a polyherin promoter for high-level expression. Since 
the restriction sites chosen to clone S401-1000 into the transfer vector pVL1393 
(Invitrogen, USA) (Figure 3.2) were the same as that from the construction 
PET-S401-1000, the S401-1000 gene fragment was obtained by digestion of PET-S401-1000 
with Bam H I and Not I sites at 5' and 3' termini. 
The cloning methods for constructions PVL-S401-1000 and pVL-N were the same 
as PET-S401-1000，pET-Si_400 which have been described in details in the Chapter 2. 
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Figure 3.2 Map of transfer vector pVL1393 designed for construction recombinant 
baculovims. It contained the recombinant sequence for homologous recombination 
with baculovims genome; polyhedrin promoter which is a strong promoter for 
high-level expression and multiple cloning sites. 
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3.3.2 Cloning of S401-1000 into transfer vector pFastBac HT B 
Besides pVL1393, the S401-1000 digested from construct PET-S401-1000 by Bam HI 
and Not I was also cloned into another transfer vector pFastBac HT B (Invitrogen, 
USA) (Figure 3.3) for the Bac-to-Bac® Baculovirus Expresssion System. The 
recombinant pFastBac HT B containing S401-1000 was transformed into MAX 
Efficiency® DHlOBac™ cells which possesses bacmid and helper plasmid. After 
verification of the transformation process by PCR analysis, this recombinant bacmid 
is ready for transfecting insect cells. The whole process is summarized in the Figure 
3.4. 
The S401-1000 fragment cloned into this transfer vector, called clone Bac-S4oi-iooo, 
is under the control of AcMNPV polyhedrin promoter which allows a high-level 
expression in insect cells. This expression cassette is flanked by the left and right 
arms of Tn7 which is a site-specific transposon to generate recombinant bacmid DNA. 
The baculovirus shuttle vector (bacmid DNA) with Tn7 target sites and a helper 
plasmid were contained in DHlOBac™ E.coli strain. The transposition reaction 
occurs in the presence of transposition proteins supplied by the helper plasmid. 
Bac-to-Bac baculovirus expression system has simplified the process of 
purifying recombinant virus by transfection of recombinant bacmid DNA into the 
insect cells instead of cotransfection of transfer vector and wild type viral genome in 
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Figure 3.3 Map of transfer vector pFastBac HT A is the same as pFastBac HT B and 
pFastBac HT C except that the frameshift occurs at the Bam HI restriction site in each 
vector. 
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Figure 3.4 The generation of recombinant baculovirus and the expression of the gene 
of interest using the Bac-to-Bac baculovirus expression system. 
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the traditional method. 
3.3.3 Virus works 
3.3.3.1 BmN cells and Sf9 cells culture 
The cells were cultured in complete insect cell culture medium in 75cm^ culture 
flasks or 100mm culture dishes (both from Coming®, Coming, N. Y.) at 27°C. Cells 
were subcultured by scraping them off with a sterilized rubber policeman every three 
days or before 100% confluence. 
3.3.3.2 BmNPV and AcMNPV 
BmNPV or AcMNPV was propagated and amplified by in vitro infection of 
BmN or SF9 cells respectively. The culture medium of infected cells was saved as the 
viral stock and was stored at 4°C. 
3.3.3.3 Infection of recombinant BmNPV or AcMNPV 
The BmN or SF9 cells growing in log phase (1-2x10^ cells/mL) were seeded to 
culture dishes the day before infection (at 1.8x10^ cells for each 60mm dish and 
5.5x10。cells for each 100mm dish) and incubated at 27 °C overnight. Before 
infection, the complete insect cell culture medium was discarded and replaced with 
minimal volume of the infection medium. An appropriate volume of virus was 
inoculated. The infection process was carried out at room temperature for one hour 
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with gentle and even rocking of the culture dishes at 15-min interval. 
3.3.3.4 Isolation of occlusion bodies and extraction of wild-type BmNPV particles 
(Maeda, 1989) 
Ten milliliters of the wild-type BmNPV-infected hemolymph was centrifuged at 
room temperature at 3500 rpm for ten minutes. The supernatant with oily debris was 
removed carefully. The pellet containing occlusion bodies was resuspended in 4mL 
occlusion body lysis buffer. The lysis mixture was mixed gently and kept on ice for 30 
minutes. After that, it was centrifuged at 3500 rpm at room temperature for ten 
minutes. The supernatant with the released wide-type BmNPV particles was saved. 
The pellet was subjected to another round of lysis to extract virus particles from any 
unlysed occlusion bodies. The supematants were pooled and stored at 4°C for 
subsequent extraction of viral genomic DNA. 
3.3.3.5 Purification of wild-type BmNPV genomic DNA 
Two milliliters of the extracted BmNPV particles was layered onto ImL 40% 
(w/v) sucrose cushion in a 4.5mL-polyallomer ultracentrifuge tube (Beckman) and 
centrifuged at 30000 rpm at 15。C for one hour. The viral pellet was saved and 
resuspended in 400 / / L TE buffer. 0.05 volume of Proteinase K (Sigma, St. Louis, 
MO) at 20mg/mL and 0.1 volume of 10% (w/v) SDS solution were added to lyse the 
viral coat proteins at 55°C for one hour. One volume of phenol /chloroform was then 
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added to extract the viral genomic DNA by mixing the content back-and-forth slowly 
for ten minutes. The mixture was centrifuged at 13000 rpm at 4。C for five minutes 
and the aqueous upper layer containing the viral DNA was saved. The extraction 
process was repeated twice with phenol/chloroform and two more times with 
chloroform alone. The organic layers were pooled and back-extracted by adding 
100-200 P.LTE buffer and re-centrifuged at 13000 rpm at 4°C for five minutes. The 
aqueous layers were pooled. The integrity of the purified viral DNA was checked by 
agarose gel electrophoresis. The DNA preparation was stored at 4°C. 
3.3.3.6 Cotransfection of wild-type BmNPV genomic DNA with recombinant 
pVL1393 transfer vector into BmN cells to generate recombinant BmNPV 
Four micrograms recombinant pVL1393 transfer vector together with 8 mg 
BmNPV wide-type DNA were made up to 300/zL with Grace's insect cell culture 
medium (solution A) just before transfection. Meanwhile, 60 // L of 
LipofectAMINE™ reagent (2mg/mL) from GibcoBRL (Gaithersburg, M. D.) were 
made up to 300 j i L with Grace's insect cell culture medium (solution B). Solution B 
was slowly added to solution A, and the mixture was incubated at room temperature 
for one hour to form a DNA-liposome complex. Afterwards, 2.4mL Grace's insect cell 
culture medium was then slowly mixed with the DNA-liposome mixture. BmN cells 
in log phase were seeded to 60mm dishes to 60% confluence the day before 
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transfection. They were washed twice with Grace's insect cell culture medium before 
the experiment. The DNA-liposome mixture was gently applied to the BmN cells, and 
transfection was allowed to proceed at 27°C for 5 hours. Three milliliters of recovery 
culture medium was added to stop the transfection process. The transfected BmN cells 
were incubated at 27°C for another 19 hours. The medium was then replaced with 
3mL complete insect cell culture medium and incubated at 27°C for 6 days. The 
success of the transfection was confirmed by the presence of occlusion bodies. On day 
6，the culture medium was harvested with cell debris removed by centrifugation at 
room temperature at 401-1000 rpm for 5 minutes. This transfection stock was stored at 4 
°C and used to generate the first progeny of the recombinant viral stock PI. 
3.3.3.7 Transfection of Bac-S4oi-iooo into insect cell line Sf9 to generate recombinant 
AcMNPV 
According to the instructions supplied by Invitrogen, 9x10^ Sf9 cells were 
seeded in 35mm tissue culture plate and allowed to attach at 27°C for 1 hour. For 
each transfection sample, 8/zg of purified recombinant DNA were made up to 100// 
L clean medium (solution A) and mixed by gently rotation. Meanwhile, 6 / / L of the 
Cellfectin® Reagent (Invitrogen) was mixed thoroughly in 100/ /L clear medium 
(solution B). Afterwards, solution A was combined with solution B and mixed gently 
for incubation at 45 minutes at room temperature. While incubation, insect cells were 
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washed by 2mL of clear medium once before the transfection. The DNA-lipid 
complexes were gently applied to Sf9 cells, and transfection was allowed to proceed 
at 27°C for 5hours. The DNA-lipid complexes were removed and 2mL of complete 
Grace's culture medium were added to the cells. The cells were incubated at 27°C for 
another 72 hours. The changes of cell morphology indicated the success of 
transfection. 
3.3.3.8 Plaque assay with viral plaque lifting to purify rS4oi-iooo(BMN) and rN(BMN) 
The infection stock serially diluted to 10'^  — 10"^  fold in infection medium was 
used to infect BmN cells seeded in 60mm dishes at 1.8x10^ cells/dish. Mock-infected 
control was also performed. The volume of infection inoculum was ImL/dish. 
Agarose medium was overlaid onto the BmN cells. On day 6, the agarose overlays 
were gently scratched and each of them was transferred to a larger sterile culture dish 
with the cell-side facing upward. A piece of autoclaved 0.45 j i m pore-size protein 
transfermembrane (Schleicher & Schuell, Germany) cut to 60mm in diameter was 
gently put onto each overlay. The membranes were allowed to soak for five minutes. 
A 23-G needle (Terumo) dipped in sterile black ink was used to pierce the membrane 
with the agarose overlay at three asymmetric positions. The membrane were then 
lifted with forceps and dried at room temperature for 10 minutes with the agarose-side 
up. After air-drying, the membrane with viral protein was ready for western blotting. 
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3.3.4 Identification of recombinant BmNPV or AcMNPV 
3.3.4.1 PCR analysis of recombinant baculovims 
PCR analysis can be used to identify the presence of insert by applying the 
specific primers. Before PCR, the viral genome DNA should be first extracted from 
0.4mL viral stock. 0.05 volume of proteinase K with the concentration at 20mg/mL 
and 0.1 volume of 10% (w/v) SDS solution were added to the viral stock and 
incubated at 55°C for Ihour to digest the viral coat. The wash buffer and column for 
the Concert rapid gel extraction system (GibcoBRL, USA) was applied. At last, 35 // 
L of ddHaO was used to elute the DNA. The same PCR profiles as mentioned above 
were performed. 
3.3.4.2 Identification the presence of recombinant baculovims by western blotting 
The cell pellet from infection viral stock was first lyzed by ddHaO to release the 
viruses. The mixture was then centrifuged at 13000rpm to get rid of the cell debris. 
The supernatant was ready for western blotting. Specific antibody was used to 
identify protein expressed in baculovims. 
3.3.5 Manipulation of silkworm 
3.3.5.1 Rearing of silkworm 
Silkworms were provided by Dr. Z. Q. Meng of the Zhejiang Academy of 
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Agricultural Sciences, Hangzhou. They were cultivated in spacious plastic trays at 27 
°C and fed with fresh mulberry leaves or artificial diet from Hangzhou. 
3.3.5.2 Infection of silkworms with recombinant BmNPV and extraction of hemolyph 
(Choudary et al., 1995) 
Silkworms at early fifth instar (one to three days after molting, body weight 
between 2.5 to 4.0g) were used for infection. Larvae were starved for three hours 
before viral infection. At the same time, recombinant BmNPV was diluted ten-fold in 
Grace's insect cell culture medium supplemented with IxPSF to -LSxlO"^ pfu// /L. 
Silkworms were anesthetized on ice for 20 minutes and then gently cleaned with 70% 
ethanol. Twenty microlitres of the diluted vims was injected longitudinally underneath 
the dorsal cuticle of each larva by a 1/2 c.c. Ultra-Fine® II short needle insulin 
syringe (Becton Dickinson). Infected silkworms were fed as usual at room 
temperature until symptoms of severe viral infection were observed (e.g. cessation of 
food consumption and movement, yellow cuticles and softened body texture). To 
collect the hemolymph, prolegs of the silkworms were cut with scissors and 
hemolymph was squeezed into a sterile 1.5mL eppendorf tube. Dithiothreitol (DTT) 
was immediately added to a final concentration of 5-lOmM to prevent melanization. 
The hemolymph was kept at 4°C for occlusion body extraction or flash-frozen in 
liquid nitrogen and then stored at -80 °C for recombinant rN(BMN) protein 
78 
Baculovirus expression and purification 
purification. 
3.3.6 Mouse immunization for polyclonal antibody against rN(E) protein 
Six to eight week-old BALB/c mice were immunized subcutaneously (SC) with 
50/ i g of rN(E) emulsified with complete Freund's adjuvant (CFA). After 21 days, 
mice were boosted SC with the same amount of the antigen emulsified with 
incomplete Freund's adjuvant (IFA). The SC injection was repeated after 14 days. A 
final booster with the same amount of the antigen without adjuvant was injected to the 
mice intraperitoneally (IP) 14 days after the third injection. At last, mice sera were 
collected and used as the first antibody against N protein. The polyclonal antibody 
was applied to identify the N protein expressed from baculovirus rN(BMN). 
3.4 Results 
3.4.1 Expression of rN(BMN) in baculoviruses 
3.4.1.1 Validation of immunoreactivity of mouse anti-rN(E) serum using SARS viral 
lysate 
rN(E) obtained as described in section 3.3.6 was used to immunize mouse. The mouse 
serum collected served as polyclonal antibody for the detection of rN(BMN) 
expressed in baculovirus. The whole SARS viral lysate was used to validate the 
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anti-rN(E) serum. As shown in the Figure 3.5，a band with a molecular weight similar 
to N protein from whole SARS viral lysate reacted with this anti-rN(E) serum 
indicating that the antibodies produced by immunization with rN(E) could be used to 
detect the native N protein. 
3.4.1.2 Purification of recombinant baculovims by plaque assay 
The purification of recombinant baculovims was done according to the section 
3.3.3.8. The rN(BMN) expressed from recombinant baculovims was monitored by 
western blot using anti-rN(E) serum. A gradual enrichment of positive signals in every 
subsequent round of purification is expected. As indicated in the Figure 3.6, the 
number of positive signals increased in each round of purification. The enrichment of 
these positive signals illustrated that the recombinant baculovims was concentrated. 
The similar purification process was repeated ti l l the virus stock produced no 
occlusion body when it was used to infect BmN cells. 
3.4.1.3 PGR analysis of recombinant baculovims stock 
PCR was used to determine i f the N gene was present in the rN(BMN) 
recombinant baculovims. As indicated in the Figure 3.7, DNA extracted from the viral 
stock produced a PCR band similar to the positive control. This indicates that the 
recombinant baculovims probably contained the DNA sequence of the N protein. 
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Figure 3.5 SDS-PAGE (A) and Western blotting (B) analysis of whole SARS viral 
lysate. In the western blot, mouse serum immunized with rN(E) served as the first 
antibody to detect the native N protein in the lysate. Lane 1: protein marker; Lane 2: 
whole SARS viral lysate. 
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Figure 3.6 The purification process for the recombinant rN(BMN) baculovims. The 
positive signals were enriched round by round. The red circles indicated some of the 
example spots. The A, C and E were mock infected cells for comparison. 
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Figure 3.7 PCR analysis of viral DNA from rN(BMN) recombinant baculovirus. Lane 
1： lOObp DNA ladder; Lane 2: MassRuler DNA Ladder (1Kb); Lane 3: PCR product 
of clone pVL-N as positive control; Lane 4: negative control, DNA extracted from 
mocked infected cells; Lane 5 - 7 : different viral DNA fractions extracted from 
infected cells. 
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3.4.1.4 In vitro expression and purification of recombinant rN(BMN) 
rN(BMN) was first expressed in a 50mL scale cell culture by infection of the 
purified recombinant baculovims stock. Since we do not have the reagents to develop 
a sensitive sandwich ELISA to quantitatively detect the level of rN(BMN) expressed 
during infection, the amount of rN(BMN) could only be calculated using the Bradford 
assay after purification of this batch of material. After 6 days of infection, both cell 
pellet and the medium were harvested respectively. For the preparation of cell pellet, 
it was first lyzed by ddHsO for two minutes and then centrifuged at 13,000 rpm for 5 
minutes to get rid of the cell debris. Right before the purification, the medium and the 
prepared cell pellet were dialyzed with the start buffer. Since we have engineered the 
recombinant rN(BMN) with the His-tag fusion, we first tried to purify the target 
protein by IMAC. We purified the rN(BMN) from the cell pellet and medium 
respectively to evaluate whether the protein is secretory. As indicated in the Figure 3.8, 
both the wash and elution fractions from cell pellet (I) and medium (II) were assayed 
by SDS-PAGE and western blot. In part (II)，most of the contaminating proteins were 
washed away and one intense protein band with the predicted molecular weight 
around 45kDa was found in the first elution fraction for both SDS-PAGE and western 
blot analysis, while in part (I) no protein band of rN(BMN) was apparent. This 
experiment illustrated that rN(BMN) could be purified from the medium. 
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Figure 3.8 SDS-PAGE (A) and western blot (B) analysis ofrN(BMN) purified from 
cell pellet (I) and medium (II) of a 50 ml cell culture infected with the purified 
recombinant baculovirus. Lane 1,9: protein marker; Lane 2,10: flow through; Lane 
3-5; l l -13: wash fractions; Lane 6—8; 14-16: elution fractions. 
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However, the purified rN(BMN) did not reach single-band purity. The total yield of 
rN(BMN) calculated from Bradford assay is 3.2mg/L. 
3.4.1.5 In vivo expression and purification of recombinant rN(BMN) 
Purified PVL-N BmNPV was injected into silk worms according to the method 
mentioned in the section 3.3.5. The hemolymph was collected everyday starting from 
day 1 to day 5 after infection. The amount of rN(BMN) expressed was monitored by 
SDS-PAGE and western blot using anti-rN(E) serum (Figure 3.9). As indicated, the 
protein band of rN(BMN) was begun to appear 3 day after infection by western blot 
analysis. However, on the SDS-PAGE it was impossible to visualize the rN(BMN) 
band as there were too many bands present due to other proteins in the hemolymph. In 
the western blot analysis, protein band became more intense at day 5 compared with 
that of day 3 and day 4. However, there were also other bands detected besides the 
target protein. This may be due to degradation of the protein during the last day of 
infection. Since more rN(BMN) proteins were expressed in the day 5，the hemolymph 
collected from day 5 was used for further purification. 
The hemolymph was purified by IMAC as described in Section 2.3.9.2, fractions 
were collected and assayed by SDS-PAGE and western blotting using Anti-His 
antibody. As shown in the Figure 3.10, most of the rN(BMN) was concentrated and 
eluted in the elution fractions while there were also some rN(BMN) lost during the 
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Figure 3.9 SDS-PAGE (A) and Western blot (B) analysis of rN(BMN) expressed in 
silkworm. The silkworms' hemolymphs were collected from day 1 to day 5 after 
infection. Before applied to SDS-PAGE, the hemolymph harvested was first 
centrifuged at 13,000 rpm to get rid of the debris. Lane 1: protein marker; Lane 2 - 6 : 
hemolymph collected from day 1, day 2，day 3，day 4 and day 5 silkworms after 
infection respectively. 
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Figure 3.10 IMAC fractions of hemolymph expressing rN(BMN) analyzed by 
SDS-PAGE (A) and western blot analysis (B) using anti-His antibody. Lane 1: protein 
standard; Lane 2: flow through; Lane 3 - 6 : wash fractions; Lane 7 — 9: elution 
fractions. 
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wash steps. When compared with the rN(BMN) expressed in vitro, the purity of 
rN(BMN) expressed in vivo was much lower. The total yield of the semi-purified 
rN(BMN) expressed in silkworms is 121.9mg/L hemolymph. 
3.4.2 Expression of rS4oi-iooo(BMN) and rS4oi-iooo(ACN) in baculovims 
3.4.2.1 Purification of recombinant rS4oi-iooo(BMN) baculovims by plaque assay 
The S401-1000 DNA fragment digested from the construct PET-S401-1000 by using 
restriction enzymes Bam HI and Not I was directly cloned into the transfer vector 
pVL1393. The clone PVL-S401-1000 was cotransfected with wild-type BmNPV 
genomic DNA into BmN cells as described in Section 3.3.3.6. Rounds of plaque 
assays were performed to get the purified PVL-S401-1000 baculovims according to 
Section 3.3.3.8. In Figure 3.11 (I), it can be seen that several plaques with positive 
signal were detected. For further confirmation, PCR analysis was used to determine 
whether the S401-1000 gene was present in the viral stocks infected with the positive 
plaques. As indicated in Figure 3.11 II, one of the DNA samples (lane 8) extracted 
from the viral stock produce a similar band to the positive control. However, this PCR 
band was very weak and hardly could be seen in the original gel. It illustrated that this 
viral stock contained little amount of recombinant rS4oi-iooo(BMN) baculovims and 
the amount of recombinant baculovims was much less that that of the wild type. 
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Figure 3.11 Plaque assay on r S 4 o i - i o o o(BMN) baculovims purification (I) and PCR 
analysis of plaques picked from the plate (II). (A): mocked infected cells; (B) cells 
infected with unpurified r S 4 o i - i o o o(BMN) baculovirus stock. Lane 1: lOObp DNA 
ladder; Lane 2: 1Kb DNA ladder; Lane 3: PCR product of PVL-S401-1000 used as 
positive control; Lane 4: PCR product of DNA extracted from mocked infected cells 
used as negative control; Lane 5 - 8 : different DNA samples extracted from viral 
stocks. 
90 
Baculovirus expression and purification 
rounds of plaque assay and enrichment attempts, we were still not able to purify the 
recombinant rS4oi-iooo(BMN) baculovirus. Therefore, we changed our strategy and 
used the Bac-to-Bac system to express S401-1000 in AcNPV using Sf9 cells. 
3.4.2.2 Generation of recombinant rS4o i - iooo(ACN) baculovirus 
S401-1000 was directly cloned into pFastBac™ HT B vector and transformed into 
the Bacmid by recombination as introduced in the section 3.3.2. Different amount of 
recombinant clone Bac-S4oi-iooo (4, 6, 8 and 10 / /g) was transfected into Sf9 cells. The 
medium was collected after the transfection and PCR analysis was performed for the 
confirmation of S401-1000 gene existed. As shown in the Figure 3.12, all the DNA 
samples extracted the medium produced a similar band to the positive control. It 
indicate the recombinant baculovirus generated contained the S401-1000 gene. 
3.4.2.3 In vitro expression and purification of recombinant rS4oi-iooo(ACN) 
The recombinant r S 4 o i - i o o o(ACN) viral stock was used to infect a 50mL Sf9 cell 
culture as mentioned in the section 3.3.3.3. During the infection, the sign of cell lysis 
or detachment indicated the success of infection. After 5 days of infection, the 
medium harvested was dialyzed with start buffer of purification to get rid of the 
interfering ions existing in the culture medium. Since the recombinant rS4oi-iooo(ACN) 
protein was designed to be expressed with a His-tag fusion, the protein could be 
theoretically purified by IMAC. As indicated in the Figure 3.12, the protein band of 
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Figure 3.12 PCR analysis of DNA samples extracted from different transfection cell 
supematants. Lane 1: lOObp DNA ladder; Lane 2: 1 kb DNA ladder; Lane 3: negative 
control of PCR; Lane 4: positive control of PCR; Lane 5 - 8 : DNA samples extracted 
from cell supematants transfected with 4，6，8 and 10/zg recombinant Bacmid 
respectively. 
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Figure 3.13 SDS-PAGE and western blot analysis of the purification process of 
rS4oi-iooo(ACN) from 50mL cell culture by IMAC. Lane 1: protein marker; Lane 2: 
flow through; Lane 3 - 6 : wash fractions; Lane 7 and 8: elution fractions. 
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the elution fractions shown in the western blot has a molecular weight similar to what 
we had expected. Besides, no such band existed in the flow through and wash 
fractions. Although the band similar molecular weight was found on both western blot 
and SDS-PAGE, they are not identical because the density of the band found from 
SDS-PAGE should have led to a much more stronger signal in the western blot. 
Therefore we conclude that the yield of r S 4 o i - i o o o(ACN) was so low that it was hard to 
distinguish the target band in SDS-PAGE. Based on this limited results, we believe 
that the rS4oi-iooo(ACN) was successfully expressed in the baculovims but at low level. 
Moreover, we failed to purify rS4oi- iooo(ACN) from the cell pellet collected after 
infection. rS4oi.iooo(ACN) was probably secreted out into the medium, same as 
rN(BMN). 
3.4.2.4 Confirmation of rS4oi-iooo(ACN) expression by using Rabbit-Anti-S antibody 
To further confirm the existence of r S 4 o i - i o o o(ACN) expression in baculovims, we 
used another antibody, Rabbit-Anti-S serum for the detection of the protein. This 
serum was prepared from immunized rabbit with a full S protein construct in a 
potential DNA vaccine for SARS (kindly provided by Vical, San Diego, Ca, USA). As 
shown in the Figure 3.14，the Rabbit-Anti-S serum can react specifically with 
rS4oi-iooo(ACN) while several bands were present when reacting with the anti-His 
antibody. This experiment further confirmed that we had successfully expressed 
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Figure 3.14 SDS-PAGE (A) and western blot analysis of rS4oi-iooo(ACN). (B) Western 
blot analysis of rS4oi-iooo(ACN) against Anti-His antibody. (C) Western blot analysis 
of rS4oi-iooo(ACN) against Rabbit-Anti-S serum. Lane 1: protein marker; Lane 2: 
rS4oi-iooo(ACN) purified from baculovirus infected medium. 
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rS4oi-iooo(ACN) in the baculovims. 
3.5 Discussion: 
3.5.1 The expression level of rN(BMN) in both in vitro and in vivo 
In the present study, rN(BMN) was expressed both in a 50mL scale cell culture 
and in silkworms. After 5 days of infection, a total 120mL of hemolymph was 
collected from infected silkworms. As described in the Figure 3.8, the purity of 
rN(BMN) expressed in the cell culture was relative high and the rN(BMN) can be 
accounted for roughly half of the total purified protein seen from SDS-PAGE. Since 
the total amount of protein purified from 50mL cell culture is 3.2mg/L, the yield of 
the rN(BMN) is round 1.6mg/L. Compared to the in vitro expression, the purity of 
rN(BMN) expressed in vivo was much lower as shown in the Figure 3.10. rN(BMN) 
could only account for around 10% to 15% of the total purified protein according to 
visual inspection. Therefore, the yield of rN(BMN) in vivo expression is around 12.1 
mg/L to 18.29mg/L assuming the total protein amount was 12L9mg/L. Based on 
these calculations, in vivo expression level of rN(BMN) was nearly 10 fold higher 
than that of in vitro. In our pervious study of malaria, the average expression level of 
semi-purified PfMSP-142 in silkworms was 378.86mg/L hemolymph, which was 
100-fold higher than that in BmN cell culture (3.52mg/L culture medium) (Pang 
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2000). In the case of grass carp growth hormone, the amount of hormone produced 
was around Img/ml hemolymph (Ho et al., 1998). When compared to these 
expression level, our production of rN(BMN) was relatively less and it can be further 
optimized in the future. 
We can first try to optimize the hemolymph collection time. Since we have failed 
to develop a sensitive assay up til l now, i.e. sandwich ELISA, to monitor the amount 
o f protein expressed in vivo, all the hemolymph was collected before the silkworms 
died. We presume that more protein would be expressed i f the hemolymph could be 
collected later. By setting up a sandwich ELISA, we can then collect the hemolymph 
at a more accurate and optimized time. However, it is necessary to develop 
monoclonal anti-rN(BMN) or anti-N antibody before setting up a sandwich ELISA. 
3.5.2 rS4oi-iooo(ACN) expression in vitro 
The in vitro expression of rS4oi-iooo(ACN) in baculovirus was significantly lower 
than that of rN(BMN) in BmN cells. Several factors may contribute to this. It has 
been described in the literature that differences in the replicative ability of different 
recombinant baculoviruses could not be accountable for the difference in protein 
expression (Seetharamaiah et a l , 1999). The level of protein expression is often 
reflected by the amount of mRNA present in the cell instead of the level of viral DNA. 
Messenger RNA level is regulated either by the rate of transcription or by the stability 
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of mRNA. For further study of the expression level of rS4oi - iooo(ACN), we could 
performed Northern blot analysis or quantitative PCR to assess the mRNA level. For 
comparison, rN(BMN) could be used as a positive control. In a previous study, our 
laboratory has compared the expression level of different malaria MSPl-42kD 
constructs in BmN cells (Pang 2000), the difference in mRNA level was not 
comparable to that of the proteins. In a similar investigation, Seetharamaiah et al. 
noticed that there were considerable amounts of transcripts at all times in all Sf9 cells 
irrespective of the recombinant virus used for infection. Therefore, we conclude that 
the main factor contributing to protein expression level is due to translational 
regulations. In this regard, protein stability and mRNA secondary structure may 
control the expression of rS4o i - iooo(ACN) in Sf9 cells. Since rS4o i - iooo(ACN) is 
secretory, the low level of rS4o i - i ooo(ACN) suggested that the intracellular form may 
be inherently unstable, e.g. rapidly degraded after expression. 
In Sf9 cells, it has been observed that protein ubiquitination was responsible for 
tagging proteins to specific cellular compartments for degradation (Low et al., 1995). 
Another concern is the mRNA secondary structure which controls translational 
efficiency. The ATP-dependent unfolding of the mRNA secondary structure is 
governed by the eukaryotic initiation factor (elF), eIF4F, which is a complex of three 
polypeptides, eIF4E, eIF4A and eIF4G (Londei et al., 1998). I f any of these initiation 
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I 
factors do not function optimally, then the complex RNA secondary structure wil l be 
I 
maintained, thus negatively affecting the translational efficiency. At the moment, we 
do not know how the r S 4 o i - i o o o(ACN) protein production is translationaly regulated. 
Whether the mRNA secondary structure or “ protein instability “ could account for 
this low expression level remains to be determined later. 
3.5.3 Failure in generating r S 4 o i - i o o o(BMN) 
Although we have successfully generated rN(BMN) recombinant BmNPV, we 
failed to purify r S 4 o i - i o o o(BMN) BmNPV from the wide-type. The whole recombinant 
baculovirus purification process is very time and labor consuming specially by 
performing the plaque assay. In each plaque picked, the amount of the recombinant 
baculovirus theoretically should be larger than that of the wild type i f the plaque was 
correctly identified. However, even in such condition, the very little amount of 
wild-type baculovirus would replicate much more quickly in the enrichment process 
than the recombinant ones. This may increase the rounds of purification needed. The 
success in purifying rN(BMN) recombinant BmNPV relied mainly on the availability 
of a high tittered anti-rN(E) serum. Strong signals could be obtained in each round of 
plaque assay by western blot and this made the process easier by picking bigger and 
more obvious plaques. To overcome the difficulty in purifying r S 4 o i - i o o o(BMN) 
BmNPV due to the lack of a good antiserum, we changed to the Bac-to-Bac system to 
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generate recombinant AcNPV in a single step. Unfortunately, the expression level of 
rS4oi-iooo(ACN) by this method was very low. For the further work, the purification of 
rS4oi-iooo(BMN) could be continued by developing a high titer antibody/antiserum. 
Limiting dilution may also be performed i f there is a monoclonal antibody against 
S401-1000 or full-length S protein available. Al l these improvements wil l somehow 
shorten the time for virus purification. Otherwise, northern blot which gives stronger 
signals than western blot could be tried in the plaque assay. Since this approach 
detects the expression from transcriptional level, other confirmation methods are 
needed to evaluate i f the protein was successfully expressed. 
3.5.4 Purification ofrN(BMN) by IMAC 
Our results indicated that the purity of rN(BMN) expressed in silkworms was 
very low. Since the use of silkworms to express target protein is a cost-effective way, 
it is essential to get higher purity i f our goal to produce a vaccine for the prevention of 
SARS is to been realized. It was obvious that IMAC is not a good method for 
purifying rN(BMN). Other purification methods are required. In our lab, a number of 
chromatography methods have been evaluated to purify proteins expressed in 
silkworms. Among them, immunoaffinity chromatography using antibody coupled to 
Sepharose appeared to be the best method as it could effectively separate the protein 
from other contaminants (Pang 2000). This method may have concerns in preparation 
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of materials for human clinical trial because proteins purified by immunoaffinity 
chromatography require additional demonstration of safety as required by regulatory 
agencies such as the Food and Drug Administration (FDA) of USA. For instance, i f 
using murine monoclonal antibodies, the affinity column must be free of contaminants 
such as DNA and viruses, and the purified protein products must be free of 
immunoglobulins that may have leached from the affinity column (Chang, 1994). One 
successful example in the use of immunoaffinity chromatography for the preparation 
of a clinical-grade recombinant protein is human Factor VI I I for the treatment of 
hemophilia A (Schwartz et al., 1990). In addition to use immunoaffinity 
chromatography to purify the rN(BMN) expressed in silkworms, the development of 
anti-rN(E) antibody or other anti-N antibody is needed. Therefore, the generation of 
monoclonal anti-N antibody should be an essential part of future work. 
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Chapter 4 Characterization of recombinant rSi.4oo(E), rN(E), rN(BMN), 
rS4oi-iooo(E) and rS4oi.iooo(ACN) 
4.1 Introduction 
In this part, all the proteins expressed from both the bacterial and baculovirus 
systems were characterized by Western blot or ELISA. The immunoreactivies of these 
recombinant proteins were assayed by reacting against a horse Anti-SARS serum and 
sera from SARS recovered patient. Both types of sera are believed to have antibodies 
against the native SARS-CoV. Theoretically, these sera can recognize the native 
SARS proteins and the immunoreactivities of the recombinant SARS proteins can be 
distinguished by analyzing the specificities of the interactions between the proteins 
and the sera, i.e. the strongest immunogen is supposed to have the most 
immunostimulating effect. Moreover, these two types of sera represent different 
stages of SARS-CoV infection. From the manufacture's description (Advantek 
Biologies, Hong Kong), the horse serum was collected after vaccination with 
formaldehyde-inactivated SARS virus, which indicates that the horse serum can 
represents the acute-phase of SARS-CoV infection. In the case of the SARS patients 
sera, all the sera were collected from the recovered SARS patients, indicating that 
they represent the immunostatus in the convalescent-phase of SARS-CoV infection. 
102 
Characterization 
Therefore, these sera should enable us not only to analyze the immunoreactivities of 
our recombinant SARS proteins but also to analyze the roles of these proteins in 
stimulating humoral immunity at different stages of the infection. 
4.2 Materials 
4.2.1 Reagents for enzyme-linked immunosorbent assay (ELISA) 
4.2.1.1 ELISA coupling buffer 
It was prepared by dissolving 1.6 g NasCO] and 2.9 g NaHCOs in I L dHaO. The 
pH of the solution was adjusted to 9.6 with I M HCl. 
4.2.1.2 Washing buffer 
It was PBST mentioned in the section 4.2.2.2. 
4.2.1.3 Blocking buffer 
It was PBST containing 3% (w/v) non-fat dried milk powder. 
4.2.1.4 Saturation buffer 
It was prepared by dissolving 1% (w/v) bovine serum albumin (BSA) in PBS. 
4.2.1.5 Secondary antibody buffer 
It was prepared by dissolving 1% (w/v) BSA in PBST. 
4.2.1.6 Horseradish peroxidase (HRP) substrate buffer 
It was lOOmM tri-sodium citrate solution with pH adjusted to 4.1 with I M HCl. 
103 
Characterization 
4.2.1.7 HRP substrate mix 
A 5Ox ABTS stock solution was prepared by dissolving 0.499 g 2, 
2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt (ABTS) in 
20mL HRP substrate buffer. One mL aliquots were prepared and kept at -20°C. Just 
before use, one aliquot of ABTS was warmed at 37。C. For each milliliter of substrate 
solution, 20juL 5Ox ABTS solution and 1.4//L 30% (v/v) H2O2 were made up to 
ImL with HRP substrate buffer. 
4.2.2 Reagents for purification of human IgG 
4.2.2.1 Elution buffer 
It was composed of lOOmM glycine and pH was adjusted to 2.7. The buffer was 
filtered with 0.45 // m pore-size membrane and chilled at 4°C before use. 
4.2.2.2 Neutralization buffer 
It was composed of I M Tris-HCl with pH at 9. 
4.2.3 Source and Identity of Immune sera 
4.2.3.1 SARS recovering patient sera 
Al l seven SARS recovering patient sera were collected by Professor G. Cheng, 
Dept. of Therapeutics and Medicine in the Princes Wales Hospital in Sept. 2003 from 
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medical students or doctors who have been infected by SARS-CoV. The patient sera 
were collected at least three months after recovery from SARS. In our 
characterization, we used pooled patient sera in addition to the individual ones. The 
pooled patient serum was prepared by mixing equal amount of each patient's serum in 
a pool ofseven. 
4.2.3.2 Normal human serum 
The normal human serum in the characterization was collected from a normal 
person who has not exposed to SARS. 
4.2.3.3 Anti-SARS Antibody (Equine) 




Protein samples were diluted in ELISA coupling buffer with the concentration of 
5 {1 g/ml and were coated onto 96-well MaxiSorp polystyrene plates (Nalge Numc 
International, USA) at 100/zl/well at 4°C overnight. The plates were flicker-dried 
and washed three times (5 min each) with 200 f i 1/well of blocking buffer. The plates 
were then saturated with 200 (i 1/well of saturation buffer at room temperature for one 
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hour. After saturation, the plates were flicker-dried and washed three times (5 min 
each) with 200 // 1/well of washing buffer. First Mab or mouse anti-serum (will be 
specified in each case) diluted in saturation buffer was added in a volume of 100// 
1/well and the plates were incubated at room temperature for one hour. The plates 
were flicker-dried and washed five times (5 min each) with 200 // 1/well of blocking 
buffer. EIA-grade affinity purified goat-anti-mouse IgG (H+L) HRP-conjugate 
(Bio-Rad, USA) or goat-anti-human IgG HPR-conjugate (Jackson ImmunoResearch, 
Europe) was diluted 2000-fold in secondary antibody buffer and added into the wells 
at 100// 1/well. The plates were then incubated at room temperature for one hour. 
Finally, the plates were flicker-dried and washed three times (5 min each) with 
blocking buffer and then twice (5 min each) with wash buffer, at 200 [ i 1/well. The 
HRP substrate mix was added at 100/z 1/well and color development was performed 
by incubating the plates at 37°C for 20 min. Optical density at 405nm (OD405) was 
measured by a microplate reader (Bio-Rad, USA). 
4.3.2 Purification of human IgG 
The pre-packed column used was HiTrap^^ Protein G HP which was purchased 
from Amersham (USA). Before use, the column was washed by ddHsO for 3 bed 
volumes. Afterwards, 3 bed volumes of PBS was also required to equilibrate the 
column. Before loading, the sample was thawed and diluted 4 times with the chilled 
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PBS. Samples were reloaded 3 times for a better binding. The column was then 
washed with 5 bed volumes of PBS. The sample was eluted by 10 bed volumes of 
elution buffer. The elution fractions collected were neutralized immediately by 300 j i 1 
of the neutralization buffer. They were now ready for assay by SDS-PAGE or western 
blotting. After use, the column should be washed with 3 bed volumes of ddHzO and 
followed by 3 bed volumes of 20% ethanol. The column was kept at 4°C till use next 
time. 
4.4 Results 
4.4.1 Validation of Immune sera using SARS viral lysate 
SARS patient sera and the normal human serum were mainly used in all of the 
following characterization assays described in this Chapter. Before use, we wanted to 
ascertain their immunoreactivities against a SARS viral lyate. It is a lysate prepared 
from SARS virus infected Vero cells and inactivated with 2X volume of SDS-PAGE 
buffer as described in Zhou et al.，2004. Figure 4.1 shows that two protein bands were 
noted in the western blot when the lysate was probed by a pooled SARS patient serum. 
No band was noticed in the reaction with normal human serum. Although, we are not 
sure of the identity of the proteins shown in the western blot, based on the molecular 
weight, it might be the N protein of the SARS virus. 
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Figure 4.1 Interaction of pooled SARS patient serum with SARS viral lysate. (A) 
SDS-PAGE analysis of SARS viral lysate; (B) Western blot analysis of SARS viral 
lysate against normal human serum; (C) Western blot analysis of SARS viral lysate 




4.4.2 Immunoreactivities of rSi_4oo(E) and rN(E) against pooled patients and normal 
human serum 
The immunoreactivity of rSMoo(E) and rN(E) expressed in E.coli were 
characterized by using pooled SARS patient and normal human serum. The results of 
the two ELISA are shown in the Figure 4.2 and Figure 4.3. In Figure 4.2, rSi^oo(E) 
and a malaria protein, MSP-hakDa, which was used as an unrelated protein control 
were coated onto the plate, respectively. Different dilutions of pooled patient or 
normal human serum were used as the first antibody to react against the protein 
coated. The ELISA was performed as mentioned in Section 4.2.1. As indicated in 
Figure 4.2 (A), the signal of rS 1.400(E) reacting with pooled patient serum showed 
nearly twice than that of the background or the unrelated protein at all three different 
dilutions of antiserum. It indicates that rSi•400(E) can capture more antibodies in the 
pooled patient serum. However, in the Figure 4.2 (B) no differential signal of rS 1.400(E) 
reacting against pooled patient and normal human serum was noticed. Optimizing the 
ELISA buffer, by addition of more detergent or BSA, did not have any improvements. 
Based on these results, we interprete that rS 1.400(E) was reacting against some 
antibodies existing in both pooled SARS patient and normal human serum. However, 
this interpretation can be enriched i f the unrelated protein, i.e. MSP-hakDa, can react 
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Figure 4.2 ELISA for characterization of cross-reactivity of rS 1.400(E). In (A), 
rSi-400(E) reacting against different dilutions of pooled SARS patient serum was 
compared with that of background and unrelated protein; In (B), rS 1.400(E) against 
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Figure 4.3 ELISA for characterization of rN(E). In (A), rN(E) reacting against 
different dilutions of pooled SARS patient serum was compared with that of 
background and unrelated protein; In (B), rN(E) against different dilutions of pooled 
patient serum and normal human serum were compared. 
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with SARS pooled patient serum. This help to confirm that only rS 1.400(E) can react 
with both SARS patient serum and normal human serum. The unrelated protein 
cannot recognize the antibodies existing in the normal human serum. Based on the 
data on hand, we conclude that the reaction observed in the Figure 4.2 (A) was not 
specific. This may be due to the cross reaction of the rS^ooCE) with normal human 
serum, which has the possibilities to be infected by other human coronaviruses. 
A similar ELISA was carried out using rN(E) instead of rS 1.400(E) coated onto the 
plate. The results are shown in the Figure 4.3. We observed that the signal of rN(E) 
against patient serum was nearly four times than that of the background or the 
unrelated protein at most of the lower diltions of antiserum (Figure 4.3.(A)). What is 
more, the signal of rN(E) against patient serum was twice than that of normal human 
serum (Figure 4.3 (B)). Based on these results, we found that rN(E) could react 
specifically with the pooled SARS patient serum. 
For further confirmation, both immunoreactivities of rS 1.400(E) and rN(E) were 
tested against pooled patient serum and normal human serum using western blot. As 
shown in the Figure 4.4，when the same amount of rSi-400(E) and rN(E) were loaded 
into the SDS-PAGE gel, only rN(E) can be detected using the pooled patient serum. 
No band was detected with either the rSi-400(E) protein or normal serum. 
These experiments illustrated that the only rN(E) can react specifically with 
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SARS patients sera while the rSi•400(E) cannot. 
4.4.3 Comparison of rN(E) and rN(BMN) immimoreacitivies 
Both rN(E) expressed from E.coli and rN(BMN) expressed from baculovims 
were investigated by western blot reacting against the seven individual SARS patient 
sera. As shown in the Figure 4.5，both N proteins can be detected when reacted 
against the individual patient sera. However, the intensity of the positive signals 
varied among different serum samples. This may be caused by the difference in titer 
of the antibodies in the sera. 
4.4.4 Comparison of the immunoreactivities of rS4o 1-1000(E) and 18401-iooo(ACN) 
In this experiment, SARS patient IgG and normal human IgG were first prepared 
according to the method described in Section 4.3.2 in order to reduce nonspecific 
binding arising from the use of the whole human serum. In the reducing SDS-PAGE, 
purified human serum IgG can be resolved into two bands of approximately 50kD and 
25kD respectively, i.e. a heavy and light chain (Tong et al., 2000). As indicated in 
Figure 4.6, both the purified IgG fractions from SARS patient and normal human 
serum exhibited the two expected bands. Western blot aganlysis using goat 
anti-human IgG demonstrated that these bands were indeed IgG in nature. 18401-1000(E) 
expressed from E. coli and rS4oi-iooo(ACN) expressed from Sf9 were investigated by 
western blot analysis using the above IgG preparations. In addition, we used rN(BMN) 
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Figure 4.4 SDS-PAGE (A) and Western blot analysis of rS 1.400(E) and rN(E) reacting 
against pooled SARS patient serum (B) and normal human serum (C). Lane 1: protein 
marker; Lane 2: rSi_4oo(E); Lane 3: rN(E). 
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Figure 4.5 SDS-PAGE (A) and Western blot analysis ofrN(E) and rN(BMN) reacting 
against seven individual SARS patient sera (B) - (H). Lane 1: protein marker; Lane 2: 
unrelated protein (MSP-hakDa fusion protein); Lane 3: rN(E) expressed from E.coli', 
Lane 4: rN(BMN) expressed from baculovirus. 
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Figure 4.6 Purification of IgG fractions. SDS-PAGE (A) (C) and western blot (B) (D) 
analysis of fractions from SARS patient (I) and normal human serum (II). Lane 1，13: 
protein standard; Lane 2，14: flow through; Lane 3-6，15-17: wash fractions; Lane 
7-12, 18-23: elution fractions. 
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Figure 4.7 Western blot analysis of rN(BMN), rS4oi-iooo(E) and rS4oi-iooo(ACN) 
reacting against purified SARS patient IgG (A) and normal human IgG (B). Lane 1: 
protein marker; Lane 2: rN(BMN); Lane 3: rS4o i - iooo(E) and Lane 4: rS4oi - iooo(ACN). 
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as a positive control, as it had been proven to react against SARS patient sera. As 
shown in the Figure 4.7, both rN(BMN) and rS4oi-iooo(E) can react with the purified 
SARS patients IgG However, the immunoreactivity between rS4oi-iooo(ACN) and the 
patients IgG was too weak to be detected. This may be due to the very low amount of 
rS4oi-iooo(ACN) protein loaded onto the gel because the sample was very diluted. 
Since we have loaded the same amount of rN(BMN) in this experiment as that 
demonstrated in Figure 4.5, the weaker signal observed in Figure 4.7 probably 
indicates that the patient serum we have used in this experiment might have a reduced 
titer due to long time storage. I f this interpretation is correct, the signal of rS4oi-iooo(E) 
reacting against patient IgG in the Figure 4.7 should have been stronger i f antiserum 
had not deteroiated. Moreover, none of these proteins were found to react with the 
purified normal human IgG. 
4.4.5 Immunoreactivity of SARS related proteins against Anti-SARS Antibody 
(Equine) 
For further investigation, all the SARS related proteins expressed in the present 
study including rN(E), rN(E), rS4oi-iooo(E) and rS4oi-iooo(ACN) were evaluated by an 
Anti-SARS serum raised in horse(ABL, HK). This serum was collected during the 
acute phase of SARS-CoV immunization which represents a different stage from the 
SARS recovered patient serum. What is more, this serum was supposed to contain a 
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higher titer of antibody because some of the antibodies may decline during the 
convalescent-phase of infection. As shown in the western blot (Figure 4.8), all the 
proteins tested can be detected against the Anti-SARS horse serum at the same 
dilution. We found that the immunoreactivities of all these proteins were not very 
strong except rS4oi-iooo(ACN) and rN(E). From the view of Figure 4.8 (C), both 
rS4oi-iooo(E) and rS4oi-iooo(ACN) were too weak to be detected in the SDS-PAGE 
while the protein band of rN(E) was quite clear. The amount of rS4oi-iooo(ACN) loaded 
was even less than that of rS4oi-iooo(E). However, the positive signal of rS4oi-iooo(ACN) 
in the western blot was stronger than that of rN(BMN) and rS4oi-iooo(E). When 
compared with rN(E), the positive signal of rS4oi-iooo(ACN) shown in the western blot 
has nearly the same intensity as that of rN(E). Yet from the SDS-PAGE, it is very 
clear that the protein concentration of rN(E) was much higher than than of 
rS4oi-iooo(ACN). In the case of BSA, acting as a negative control, no interaction with 
the antiserum was noticed even the amount of protein applied was very high (Figure 
4.8 (D)). In sum, all these support that the rS4oi-iooo(ACN) had the strongest 
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Figure 4.8 SDS-PAGE (A), (C) and western blot (B), (D) analysis of SARS related 
proteins reacting against anti-SARS antibodies. Lane 1，3: protein marker; Lane 2: 
rN(E); Lane 4: BSA(negative control); Lane 5: semi-purified rN(BMN) with 





4.5.1 Comparison of the immunoreactivities of the SARS related proteins expressed 
in the present study 
We compared the immunoreactivities of rSMoo(E) and rN(E) which were first 
expressed from E. coli by western blotting and ELISA. We found that only rN(E) can 
react specifically with SARS patient sera while rS 1.400(E) cannot. Because of this, 
S m o o was omitted for later study. Since the immunoreactive moiety of the S protein 
may lie close to the C-terminal, i.e. SII fragment, S401-1000，and N protein were chosen 
to be expressed in baculovims expression system as well as in E. coli. We tried to 
compare whether there is a difference between the eukaryotic and prokaryotic 
expression systems. We found that the recombinant proteins rS4oi-iooo(E), rN(E) and 
rN(BMN) can react against the SARS patient serum which represented the 
convalescent stage of infection. In contract, the interaction between rS4oi-iooo(ACN) 
and SARS patient serum could not be detected. This might have been due to the very 
low concentration of 18401-iooo(ACN) used in the western blot experiment. Moreover, 
we observed that rS4oi-iooo(ACN) could react more strongly with the horse Anti-SARS 
serum. As this horse Anti-SARS serum contained polyclonal antibodies derived from 
a horse vaccinated with formaldehyde-inactivated SARS virus (ABL, HK), it may 
represent a population of antibodies from an acute stage of the vims infection. Taken 
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together, the results suggest that, from a vims infection cycle viewpoint, S401-1000 
which is an essential part of the SII subunit probably is the first protein seen by the 
immune system during the virus's entry into the body. S401-1000 is probably the first 
protein that elicits the host immune system. This may be the reason why only S401-1000 
can react strongly with the acute serum and not the convalescent sera. This 
observation is consistent with the studies of Wong et al., (2004) and Xiao et al., (2003) 
which has demonstrated S protein mediates infection of receptor-expressing host cells 
and angiotensin-coverting enzyme 2 is a functional receptor for SARS-CoV. For the 
later stage of the virus infection, both S401-1000 and N protein play the key role in vims 
propagation. From our results, we surmise that in the convalescent stage, the N 
protein had replaced the S protein as the most essential immunogen. The 
immunological reactivity of S protein slightly decreased from the beginning of the 
virus infection. Ying et al., (2004) found that N protein could be cleaved by caspase-3 
vivo which implies that N is involved during the late phase of virus infection. Based 
on this interpretation, both S401-1000 and N protein can be good candidates for SARS 
vaccine development as both of them can elicit an immune response. 
However, this interpretation can be further confirmed by using the SARS patient 
sera during the acute phase instead of the horse anti-SARS serum. At this stage, it is 
difficult for us to ascertain whether the horse anti-SARS serum can fully represent the 
122 
Characterization 
acute phase of human infection by SARS-CoV. There may be some differences 
between the human immune system and that of the horse. Therefore, we can chase the 
patients' infection records and get the patient serum during acute phase of infection. I f 
the S401-1000 can also react more strongly with the patient serum during the acute phase 
than that of the N protein, this evidence can help firm our conclusion which states that 
the S401-1000 is the first immunogen recognized by host immune system. 
We found that S401-1000 expressed from baculovirus, rS4oi-iooo(ACN), is a strong 
immunogen than S401-1000 expressed from E.coli, rS4oi-iooo(E). However, we are not 
sure whether the fusion tag of thioredoxin in E, coli or the post-translational 
modifications in baculovirus led to such a difference in response. From our result of 
the expression of rN(E) and rN(BMN) (Figure 4.6)，we found that the size of the N 
protein varied between the two systems with the same insert. This size difference may 
be due to the post-translational modification of the baculovirus system. In the case of 
N protein, such modifications did not affect the protein's immunological reactivity 
when reacting against SARS patient sera. For further investigation, the protein 
structures of both rS4oi-iooo(ACN) and rS4oi-iooo(E) could be studied. Nevertheless, 
more purification methods should be tried to improve the poor purity of 
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Appendix (SARS full Sequence of Su-10) 
1 ctacccagga aaagccaacc aacctcgatc tcttgtagat ctgttctcta aacgaacttt 
61 aaaatctgtg tagctgtcgc tcggctgcat gcctagtgca cctacgcagt ataaacaata 
121 ataaatttta ctgtcgttga caagaaacga gtaactcgtc cctcttctgc agactgctta 
181 cggtttcgtc cgtgttgcag tcgatcatca gcatacctag gtttcgtccg ggtgtgaccg 
241 aaaggtaaga tggagagcct tgttcttggt gtcaacgaga aaacacacgt ccaactcagt 
301 ttgcctgtcc ttcaggttag agacgtgcta gtgcgtggct tcggggactc tgtggaagag 
361 gccctatcgg aggcacgtga acacctcaaa aatggcactt gtggtctagt agagctggaa 
421 aaaggcgtac tgccccagct tgaacagccc tatgtgttca ttaaacgttc tgatgcctta 
481 agcaccaatc acggccacaa ggtcgttgag ctggttgcag aaatggacgg cattcagtac 
541 ggtcgtagcg gtataacact gggagtactc gtgccacatg tgggcgaaac cccaattgca 
601 taccgcaatg ttcttcttcg taagaacggt aataagggag ccggtggtca tagctatggc 
661 atcgatctaa agtcttatga cttaggtgac gagcttggca ctgatcccat tgaagattat 
721 gaacaaaact ggaacactaa gcatggcagt ggtgcactcc gtgaactcac tcgtgagctc 
781 aatggaggtg cagtcactcg ctatgtcgac aacaatttct gtggcccaga tgggtaccct 
841 cttgattgca tcaaagattt tctcgcacgc gcgggcaagt caatgtgcac tctttccgaa 
901 caacttgatt acatcgagtc gaagagaggt gtctactgct gccgtgacca tgagcatgaa 
961 attgcctggt tcactgagcg ctctgataag agctacgagc accagacacc cttcgaaatt 
1021 aagagtgcca agaaatttga cactttcaaa ggggaatgcc caaagtttgt gtttcctctt 
1081 aactcaaaag tcaaagtcat tcaaccacgt gttgaaaaga aaaagactga gggtttcatg 
1141 gggcgtatac gctctgtgta ccctgttgca tctccacagg agtgtaacaa tatgcacttg 
1201 tctaccttga tgaaatgtaa tcattgcgat gaagtttcat ggcagacgtg cgactttctg 
1261 aaagccactt gtgaacattg tggcactgaa aatttagtta ttgaaggacc tactacatgt 
1321 gggtacctac ctactaatgc tgtagtgaaa atgccatgtc ctgcctgtca agacccagag 
1381 attggacctg agcatagtgt tgcagattat cacaaccact caaacattga aactcgactc 
1441 cgcaagggag gtaggactag atgttttgga ggctgtgtgt ttgcctatgt tggctgctat 
1501 aataagcgtg cctactgggt tcctcgtgct agtgctgata ttggctcagg ccatactggc 
1561 attactggtg acaatgtgga gaccttgaat gaggaictcc ttgagatact gagtcgtgaa 
1621 cgtgttaaca ttaacattgt tggcgatttt catttgaatg aagaggttgc catcattttg 
1681 gcatctttct ctgcttctac aagtgccttt attgacacta taaagagtct tgattacaag 
1741 tctttcaaaa ccattgttga gtcctgcggt aactataaag ttaccaaggg aaagcccgta 
1801 aaaggtgctt ggaacattgg acaacagaga tcagttttaa caccactgtg tggttttccc 
1861 tcacaggctg ctggtgttat cagatcaatt tttgcgcgca cacttgatgc agcaaaccac 
1921 tcaattcctg atttgcaaag agcagctgtc accatacttg atggtatttc tgaacagtca 
1981 ttacgtcttg tcgacgccat ggtttatact tcagacctgc tcaccaacag tgtcattatt 
2041 atggcatatg taactggtgg tcttgtacaa cagacttctc agtggttgtc taatcttttg 
2101 ggcactactg ttgaaaaact caggcctatc tttgaatgga ttgaggcgaa acttagtgca 
136 
Appendix 
2161 ggagttgaat ttctcaagga tgcttgggag attctcaaat ttctcattac aggtgttttt 
2221 gacatcgtca agggtcaaat acaggttgct tcagataaca tcaaggattg tgtaaaatgc 
2281 ttcattgatg ttgttaacaa ggcactcgaa atgtgcattg atcaagtcac tatcgctggc 
2341 gcaaagttgc gatcactcaa cttaggtgaa gtcttcatcg ctcaaagcaa gggactttac 
2401 cgtcagtgta tacgtggcaa ggagcagctg caactactca tgcctcttaa ggcaccaaaa 
2461 gaagtaacct ttcttgaagg tgattcacat gacacagtac ttacctctga ggaggttgtt 
2521 ctcaagaacg gtgaactcga agcactcgag acgcccgttg atagcttcac aaatggagct 
2581 atcgttggca caccagtctg tgtaaatggc ctcatgctct tagagattaa ggacaaagaa 
2641 caatactgcg cattgtctcc tggtttactg gctacaaaca atgtctttcg cttaaaaggg 
2701 ggtgcaccaa ttaaaggtgt aacctttgga gaagatactg tttgggaagt tcaaggttac 
2761 aagaatgtga gaatcacatt tgagcttgat gaacgtgttg acaaagtgct taatgaaaag 
2821 tgctctgtct acactgttga atccggtacc gaagttactg agtttgcatg tgttgtagca 
2881 gaggctgttg tgaagacttt acaaccagtt tctgatctcc ttaccaacat gggtattgat 
2941 cttgatgagt ggagtgtagc tacattctac ttatttgatg atgctggtga agaaaacttt 
3001 tcatcacgta tgtattgttc cttttaccct ccagatgagg aagaagagga cgatgcagag 
3061 tgtgaggaag aagaaattga tgaaacctgt gaacatgagt acggtacaga ggatgattat 
3121 caaggtctcc ctctggaatt tggtgcctca gctgaaacag ttcgagttga ggaagaagaa 
3181 gaggaagact ggctggatga tactactgag caatcagaga ttgagccaga accagaacct 
3241 acacctgaag aaccagttaa tcagtttact ggttatttaa aacttactga caatgttgcc 
3301 attaaatgtg ttgacatcgt taaggaggca caaagtgcta atcctatggt gattgtaaat 
3361 gctgctaaca tacacctgaa acatggtggt ggtgtagcag gtgcactcaa caaggcaacc 
3421 aatggtgcca tgcaaaagga gagtgatgat tacattaagc taaatggccc tcttacagta 
3481 ggagggtctt gtttgctttc tggacataat cttgctaaga agtgtctgca tgttgttgga 
3541 cctaacctaa atgcaggtga ggacatccag cttcUaagg cagcatatga aaatttcaat 
3601 tcacaggaca tcttacttgc accattgttg tcagcaggca tatttggtgc taaaccactt 
3661 cagtctttac aagtgtgcgt gcagacggtt cgtacacagg tttatattgc agtcaatgac 
3721 aaagctcttt atgagcaggt tgtcatggat tatcttgata acctgaagcc tagagtggaa 
3781 gcacctaaac aagaggagcc accaaacaca gaagattcca aaactgagga gaaatctgtc 
3841 gtacagaagc ctgtcgatgt gaagccaaaa attaaggcct gcattgatga ggttaccaca 
3901 acactggaag aaactaagtt tcttaccaat aagttactct tgtttgctga tatcaatggt 
3961 aagctttacc atgattctca gaacatgctt agaggtgaag atatgtcttt ccttgagaag 
4021 gatgcacctt acatggtagg tgatgttatc actagtggtg atatcacttg tgttgtaata 
4081 ccctccaaaa aggctggtgg cactactgag atgctctcaa gagctttgaa gaaagtgcca 
4141 gttgatgagt atataaccac gtaccctgga caaggatgtg ctggttatac acttgaggaa 
4201 gctaagactg ctcttaagaa atgcaaatct gcattttatg tactaccttc agaagcacct 
4261 aatgctaagg aagagattct aggaactgta Icctgyaatt tgagagaaat gcttgctcat 
4321 gctgaagaga caagaaaatt aatgcctata tgcatggatg ttagagccat aatggcaacc 
4381 atccaacgta agtataaagg aattaaaatt caagagggca tegttgacta tggtgtccga 
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4441 ttcttctttt atactagtaa agagcctgta gcttctatta ttacgaagct gaactctcta 
4501 aatgagccgc ttgtcacaat gccaattggt tatgtgacac atggttttaa tcttgaagag 
4561 gctgcgcgct gtatgcgttc tcttaaagct cctgccgtag tgtcagtatc atcaccagat 
4621 gctgttacta catataatgg atacctcact tcgtcatcaa agacatctga ggagcacttt 
4681 gtagaaacag tttctttggc tggctcttac agagattggt cctattcagg acagcgtaca 
4741 gagttaggtg ttgaatttct taagcgtggt gacaaaattg tgtaccacac tctggagagc 
4801 cccgtcgagt ttcatcttga cggtgaggtt ctttcacttg acaaactaaa gagtctctta 
4861 tccctgcggg aggttaagac tataaaagtg ttcacaactg tggacaacac taatctccac 
4921 acacagcttg tggatatgtc tatgacatat ggacagcagt ttggtccaac atacttggat 
4981 ggtgctgatg ttacaaaaat taaacctcat gtaaatcatg agggtaagac tttctttgta 
5041 ctacctagtg atgacacact acgtagtgaa gctttcgagt actaccatac tcttgatgag 
5101 agttttcttg gtaggtacat gtctgcttta aaccacacaa agaaatggaa atttcctcaa 
5161 gttggtggtt taacttcaat taaatgggct gataacaatt gttatttgtc tagtgtttta 
5221 ttagcacttc aacagcttga agtcaaattc aatgcaccag cacttcaaga ggcttattat 
5281 agagcccgtg ctggtgatgc tgctaacttt tgtgcactca tactcgctta cagtaataaa 
5341 actgttggcg agcttggtga tgtcagagaa actatgaccc atcttctaca gcatgctaat 
5401 ttggaatctg caaagcgagt tcttaatgtg gtgtgtaaac attgtggtca gaaaactact 
5461 accttaacgg gtgtagaagc tgtgatgtat atgggtactc tatcttatga taatcttaag 
5521 acaggtgttt ccattccatg tgtgtgtggt cgtgatgcta cacaatatct agtacaacaa 
5581 gagtcttctt ttgttatgat gtctgcacca cctgctgagt ataaattaca gcaaggtaca 
5641 ttcttatgtg cgaatgagta cactggtaac tatcagtgtg gtcattacac tcatataact 
5701 gctaaggaga ccctctatcg tattgacgga gctcacctta caaagatgtc agagtacaaa 
5761 ggaccagtga ctgatgtttt ctacaaggaa acatcttaca ctacaaccat caagcctgtg 
5821 tcgtataaac tcgatggagt tacttacaca gagattgaac caaaattgga tgggtattat 
5881 aaaaaggata atgcttacta tacagagcag cctatagacc ttgtaccaac tcaaccatta 
5941 ccaaatgcga gttttgataa tttcaaactc acatgttcta acacaaaatt tgctgatgat 
6001 ttaaatcaaa tgacaggctt cacaaagcca gcttcacgag agctatctgt cacattcttc 
6061 ccagacttga atggcgatgt agtggctatt gactatagac actattcagc gagtttcaag 
6121 aaaggtgcta aattactgca taagccaatt gtttggcaca ttaaccaggc tacaaccaag 
6181 acaacgttca aaccaaacac ttggtgttta cgttgtcttt ggagtacaaa gccagtagat 
6241 acttcaaatt catttgaagt tctggcagta gaagacacac aaggaatgga caatcttgct 
6301 tgtgaaagtc aacaacccac ctctgaagaa gtagtggaaa atcctaccat acagaaggaa 
6361 gtcatagagt gtgacgtgaa aactaccgaa gttgtaggca atgtcatact taaaccatca 
6421 gatgaaggtg ttaaagtaac acaagagtta ggtcatgagg atcttatggc tgcttatgtg 
6481 gaaaacacaa gcattaccat taagaaacct aatgagcttt cactagcctt aggtttaaaa 
6541 acaattgcca ctcatggtat tgctgcaatt aatagtgttc cttggagtaa aattttggct 
6601 tatgtcaaac cattcttagg acaagcagca attacaacat caaattgcgc taagagatta 
6661 gcacaacgtg tgtttaacaa ttatatgcct tatgtgttta cattattgtt ccaattgtgt 
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6721 acttttacta aaagtaccaa ttctagaatt agagcttcac tacctacaac tattgctaaa 
6781 aatagtgtta agagtgttgc taaattatgt ttggatgccg gcattaatta tgtgaagtca 
6841 cccaaatttt ctaaattgtt cacaatcgct atgtggctat tgttgttaag tatttgctta 
6901 ggttctctaa tctgtgtaac tgctgctttt ggtgtactct tatctaattt tggtgctcct 
6961 tcttattgta atggcgttag agaattgtat cttaattcgt ctaacgttac tactatggat 
7021 ttctgtgaag gttcttttcc ttgcagcatt tgtttaagtg gattagactc ccttgattct 
7081 tatccagctc ttgaaaccat tcaggtgacg atttcatcgt acaagctaga cttgacaatt 
7141 ttaggtctgg ccgctgagtg ggttttggca tatatgttgt tcacaaaatt cttttattta 
7201 ttaggtcttt cagctataat gcaggtgttc tttggctatt ttgctagtca tttcatcagc 
7261 aattcttggc tcatgtggtt tatcattagt attgtacaaa tggcacccgt ttctgcaatg 
7321 gttaggatgt acatcttctt tgcttctttc tactacatat ggaagagcta tgttcatatc 
7381 atggatggtt gcacctcttc gacttgcatg atgtgctata agcgcaatcg tgccacacgc 
7441 gttgagtgta caactattgt taatggcatg aagagatctt tctatgtcta tgcaaatgga 
7501 ggccgtggct tctgcaagac tcacaattgg aattgtctca attgtgacac attttgcact 
7561 ggtagtacat tcattagtga tgaagttgct cgtgatttgt cactccagtt taaaagacca 
7621 atcaacccta ctgaccagtc atcgtatatt gttgatagtg ttgctgtgaa aaatggcgcg 
7681 cttcacctct actttgacaa ggctggtcaa aagacctatg agagacatcc gctctcccat 
7741 tttgtcaatt tagacaattt gagagctaac aacactaaag gttcactgcc tattaatgtc 
7801 atagtttttg atggcaagtc caaatgcgac gagtctgctt ctaagtctgc ttctgtgtac 
7861 tacagtcagc tgatgtgcca acctattctg ttgcttgacc aagctcttgt atcagacgtt 
7921 ggagatagta ctgaagtttc cgttaagatg tttgatgctt atgtcgacac cttttcagca 
7981 acttttagtg ttcctatgga aaaacttaag gcacttgttg ctacagctca cagcgagtta 
8041 gcaaagggtg tagctttaga tggtgtcctt tctacattcg tgtcagctgc ccgacaaggt 
8101 gttgttgata ccgatgttga cacaaaggat gttattgaat gtctcaaact ttcacatcac 
8161 tctgacttag aagtgacagg tgacagttgt aacaatttca tgctcaccta taataaggtt 
8221 gaaaacatga cgcccagaga tcttggcgca tgtattgact gtaatgcaag gcatatcaat 
8281 gcccaagtag caaaaagtca caatgtttca ctcatctgga atgtaaaaga ctacatgtct 
8341 ttatctgaac agctgcgtaa acaaattcgt agtgctgcca agaagaacaa catacctttt 
8401 agactaactt gtgctacaac tagacaggtt gtcaatgtca taactactaa aatctcactc 
8461 aagggtggta agattgttag tacttgtttt aaacttatgc ttaaggccac attattgtgc 
8521 gttcttgctg cattggtttg ttatatcgtt atgccagtac atacattgtc aatccatgat 
8581 ggttacacaa atgaaatcat tggttacaaa gccattcagg atggtgtcac tcgtgacatc 
8641 atttctactg atgattgttt tgcaaataaa catgctggtt ttgacgcatg gtttagccag 
8701 cgtggtggtt catacaaaaa tgacaaaagc tgccctgtag tagctgctat cattacaaga 
8761 gagattggtt tcatagtgcc tggcttaccg ggtactgtgc tgagagcaat caatggtgac 
8821 ttcttgcatt ttctacctcg tgtttttagt gctgttggca acatttgcta cacaccttcc 
8881 aaactcattg agtatagtga ttttgctacc tctgcttgcg ttcttgctgc tgagtgtaca 
8941 atttttaagg atgctatggg caaacctgtg ccatattgtt atgacactaa tttgctagag 
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9001 ggttctattt cttatagtga gcttcgtcca gacactcgtt atgtgcttat ggatggttcc 
9061 atcatacagt ttcctaacac ttacctggag ggttctgtta gagtagtaac aacttttgat 
9121 gctgagtact gtagacatgg tacatgcgaa aggtcagaag taggtatttg cctatctacc 
9181 agtggtagat gggttcttaa taatgagcat tacagagctc tatcaggagt tttctgtggt 
9241 gttgatgcga tgaatctcat agctaacatc tttactcctc ttgtgcaacc tgtgggtgct 
9301 ttagatgtgt ctgcttcagt agtggctggt ggtattattg ccatattggt gacttgtgct 
9361 gcctactact ttatgaaatt cagacgtgtt tttggtgagt acaaccatgt tgttgctgct 
9421 aatgcacttt tgtttttgat gtctttcact atactctgtc tggtaccagc ttacagcttt 
9481 ctgccgggag tctactcagt cttttacttg tacttgacat tctatttcac caatgatgtt 
9541 tcattcttgg ctcaccttca atggtttgcc atgttttctc ctattgtgcc tttttggata 
9601 acagcaatct atgtattctg tatttctctg aagcactgcc attggttctt taacaactat 
9661 cttaggaaaa gagtcatgtt taatggagtt acatttagta ccttcgagga ggctgctttg 
9721 tgtacctttt tgctcaacaa ggaaatgtac ctaaaattgc gtagcgagac actgttgcca 
9781 cttacacagt ataacaggta tcttgctcta tataacaagt acaagtattt cagtggagcc 
9841 ttagatacta ccagctatcg tgaagcagct tgctgccact tagcaaaggc tctaaatgac 
9901 tttagcaact caggtgctga tgttctctac caaccaccac agacatcaat cacttctgct 
9961 gttctgcaga gtggttttag gaaaatggca ttcccgtcag gcaaagttga agggtgcatg 
10021 gtacaagtaa cctgtggaac tacaactctt aatggattgt ggttggatga cacagtatac 
10081 tgtccaagac atgtcatttg cacagcagaa gacatgctta atcctaacta tgaagatctg 
10141 ctcattcgca aatccaacca tagctttctt gttcaggctg gcaatgttca acttcgtgtt 
10201 attggccatt ctatgcaaaa ttgtctgctt aggcttaaag ttgatacttc taaccctaag 
10261 acacccaagt ataaatttgt ccgtatccaa cctggtcaaa cattttcagt tctagcatgc 
10321 tacaatggtt caccatctgg tgtttatcag tgtgccatga gacctaatca taccattaaa 
10381 ggttctttcc ttaatggatc atgtggtagt gttggtttta acattgatta tgattgcgtg 
10441 tctttctgct atatgcatca tatggagctt ccaacaggag tacacgctgg tactgactta 
10501 gaaggtaaat tctatggtcc atttgttgac agacaaactg cacaggctgc aggtacagac 
10561 acaaccataa cattaaatgt tttggcatgg ctgtatgctg ctgttatcaa tggtgatagg 
10621 tggtttctta atagattcac cactactttg aatgacttta accttgtggc aatgaagtac 
10681 aactatgaac ctttgacaca agatcatgtt gacatattgg gacctctttc tgctcaaaca 
10741 ggaattgccg tcttagatat gtgtgctgct ttgaaagagc tgctgcagaa tggtatgaat 
10801 ggtcgtacta tccttggtag cactatttta gaagatgagt ttacaccatt tgatgttgtt 
10861 agacaatgct ctggtgttac cttccaaggt aagttcaaga aaattgttaa gggcactcat 
10921 cattggatgc ttttaacttt cttgacatca ctattgattc ttgttcaaag tacacagtgg 
10981 tcactgtttt tctttgttta cgagaatgct ttcttgccat ttactcttgg tattatggca 
11041 attgctgcat gtgctatgct gcttgttaag cataagcacg cattcttgtg cttgtttctg 
11101 ttaccttctc ttgcaacagt tgcttacttt aatatggtct acatgcctgc tagctgggtg 
11161 atgcgtatca tgacatggct tgaattggct gacactagct tgtctggtta taggcttaag 
11221 gattgtgtta tgtatgcttc agctttagtt ttgcttattc tcatgacagc tcgcactgtt 
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11281 tatgatgatg ctgctagacg tgtttggaca ctgatgaatg tcattacact tgtttacaaa 
11341 gtctactatg gtaatgcttt agatcaagct atttccatgt gggccttagt tatttctgta 
11401 acctctaact attctggtgt cgttacgact atcatgtttt tagctagagc tatagtgttt 
11461 gtgtgtgttg agtattaccc attgttattt attactggca acaccttaca gtgtatcatg 
11521 cttgtttatt gtttcttagg ctattgttgc tgctgctact ttggcctttt ctgtttactc 
11581 aaccgttact tcaggcttac tcttggtgtt tatgactact tggtctctac acaagaattt 
11641 aggtatatga actcccaggg gcttttgcct cctaagagta gtattgatgc tttcaagctt 
11701 aacattaagt tgttgggtat tggaggtaaa ccatgtatca aggttgctac tgtacagtct 
11761 aaaatgtctg acgtaaagtg cacatctgtg gtactgctct cggttcttca acaacttaga 
11821 gtagagtcat cttctaaatt gtgggcacaa tgtgtacaac tccacaatga tattcttctt 
11881 gcaaaagaca caactgaagc tttcgagaag atggtttctc ttttgtctgt tttgctatcc 
11941 atgcagggtg ctgtagacat taataggttg tgcgaggaaa tgctcgataa ccgtgctact 
12001 cttcaggcta ttgcttcaga atttagttct ttaccatcat atgccgctta tgccactgcc 
12061 caggaggcct atgagcaggc tgtagctaat ggtgattctg aagtcgttct caaaaagtta 
12121 aagaaatctt tgaatgtggc taaatctgag tttgaccgtg atgctgccat gcaacgcaag 
12181 ttggaaaaga tggcagatca ggctatgacc caaatgtaca aacaggcaag atctgaggac 
12241 aagagggcaa aagtaactag tgctatgcaa acaatgctct tcactatgct taggaagctt 
12301 gataatgatg cacttaacaa cattatcaac aatgcgcgtg atggttgtgt tccactcaac 
12361 atcataccat tgactacagc agccaaactc atggttgttg tccctgatta tggtacctac 
12421 aagaacactt gtgatggtaa cacctttaca tatgcatctg cactctggga aatccagcaa 
12481 gttgttgatg cggatagcaa gattgttcaa cttagtgaaa ttaacatgga caattcacca 
12541 aatttggctt ggcctcttat tgttacagct ctaagagcca actcagctgt taaactacag 
12601 aataatgaac tgagtccagt agcactacga cagatgtcct gtgcggctgg taccacacaa 
12661 acagcttgta ctgatgacaa tgcacttgcc tactataaca attcgaaggg aggtaggttt 
12721 gtgctggcat tactatcaga ccaccaagat ctcaaatggg ctagattccc taagagtgat 
12781 ggtacaggta caatttacac agaactggaa ccaccttgta ggtttgttac agacacacca 
12841 aaagggccta aagtgaaata cttgtacttc atcaaaggct taaacaacct aaatagaggt 
12901 atggtgctgg gcagtttagc tgctacagta cgtcttcagg ctggaaatgc tacagaagta 
12961 cctgccaatt caactgtgct ttccttctgt gcttttgcag tagaccctgc taaagcatat 
13021 aaggattacc tagcaagtgg aggacaacca atcaccaact gtgtgaagat gttgtgtaca 
13081 cacactggta caggacaggc aattactgta acaccagaag ctaacatgga ccaagagtcc 
13141 tttggtggtg cttcatgttg tctgtattgt agatgccaca ttgaccatcc aaatcctaaa 
13201 ggattctgtg acttgaaagg taagtacgtc caaataccta ccacttgtgc taatgaccca 
13261 gtgggtttta cacttagaaa cacagtctgt accgtctgcg gaatgtggaa aggttatggc 
13321 tgtagttgtg accaactccg cgaacccttg atgcagtctg cggatgcatc aacgttttta 
13381 aacgggtttg cggtgtaagt gcagcccgtc ttacaccgtg cggcacaggc actagtactg 
13441 atgtcgtcta cagggctttt gatatttaca acgaaaaagt tgctggtttt gcaaagttcc 




13561 actttgtagt taagaggcat actatgtcta actaccaaca tgaagagact atttataact 
13621 tggttaaaga ttgtccagcg gttgctgtcc atgacttttt caagtttaga gtagatggtg 
13681 acatggtacc acatatatca cgtcagcgtc taactaaata cacaatggct gatttagtct 
13741 atgctctacg tcattttgat gagggtaatt gtgatacatt aaaagaaata ctcgtcacat 
13801 acaattgctg tgatgatgat tatttcaata agaaggattg gtatgacttc gtagagaatc 
13861 ctgacatctt acgcgtatat gctaacttag gtgagcgtgt acgccaatca ttattaaaga 
13921 ctgtacaatt ctgcgatgct atgcgtgatg caggcattgt aggcgtactg acattagata 
13981 atcaggatct taatgggaac tggtacgatt tcggtgattt cgtacaagta gcaccaggct 
14041 gcggagttcc tattgtggat tcatattact cattgctgat gcccatcctc actttgacta 
14101 gggcattggc tgctgagtcc catatggatg ctgatctcgc aaaaccactt attaagtggg 
14161 atttgctgaa atatgatttt acggaagaga gactttgtct cttcgaccgt tattttaaat 
14221 attgggacca gacataccat cccaattgta ttaactgttt ggatgatagg tgtatccttc 
14281 attgtgcaaa ctttaatgtg ttattttcta ctgtgtttcc acctacaagt tttggaccac 
14341 tagtaagaaa aatatttgta gatggtgttc cttttgttgt ttcaactgga taccattttc 
14401 gtgagttagg agtcgtacat aatcaggatg taaacttaca tagctcgcgt ctcagtttca 
14461 aggaactttt agtgtatgct gctgatccag ctatgcatgc agcttctggc aatttattgc 
14521 tagataaacg cactacatgc ttttcagtag ctgcactaac aaacaatgtt gcttttcaaa 
14581 ctgtcaaacc cggtaatttt aataaagact tttatgactt tgctgtgtct aaaggtttct 
14641 ttaaggaagg aagttctgtt gaactaaaac acttcttctt tgctcaggat ggcaacgctg 
14701 ctatcagtga ttatgactat tatcgttata atctgccaac aatgtgtgat atcagacaac 
14761 tcctattcgt agttgaagtt gttgataaat actttgattg ttacgatggt ggctgtatta 
14821 atgccaacca agtaatcgtt aacaatctgg ataaatcagc tggtttccca tttaataaat 
14881 ggggtaaggc tagactttat tatgactcaa tgagttatga ggatcaagat gcacttttcg 
M941 cgtatactaa gcgtaatgtc atccctacta taactcaaat gaatcttaag tatgccatta 
15001 gtgcaaagaa tagagctcgc accgtagctg gtgtctctat ctgtagtact atgacaaata 
15061 gacagtttca tcagaaatta ttgaagtcaa tagccgccac tagaggagct actgtggtaa 
15121 ttggaacaag caagttttac ggtggctggc ataatatgtt aaaaactgtt tacagtgatg 
15181 tagaaactcc acaccttatg ggttgggatt atccaaaatg tgacagagcc atgcctaaca 
15241 tgcttaggat aatggcctct cttgttcttg ctcgcaaaca taacacttgc tgtaacttat 
15301 cacaccgttt ctacaggtta gctaacgagt gtgcgcaagt attaagtgag atggtcatgt 
15361 gtggcggctc actatatgtt aaaccaggtg gaacatcatc cggtgatgct acaactgctt 
15421 atgctaatag tgtctttaac atttgtcaag ctgttacagc caatgtaaat gcacttcttt 
15481 caactgatgg taataagata gctgacaagt atgtccgcaa tctacaacac aggctctatg 
15541 agtgtctcta tagaaatagg gatgttgatc atgaattcgt ggatgagttt tacgcttacc 
15601 tgcgtaaaca tttctccatg atgattcttt ctgatgatgc cgttgtgtgc tataacagta 
15661 actatgcggc tcaaggttta gtagctagca ttaagaactt taaggcagtt ctttattatc 
15721 aaaataatgt gttcatgtct gaggcaaaat gttggactga gactgacctt actaaaggac 
15781 ctcacgaatt ttgctcacag catacaatgc tagttaaaca aggagatgat tacgtgtacc 
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15841 tgccttaccc agatccatca agaatattag gcgcaggctg ttttgtcgat gatattgtca 
15901 aaacagatgg tacacttatg attgaaaggt tcgtgtcact ggctattgat gcttacccac 
15961 ttacaaaaca tcctaatcag gagtatgctg atgtctttca cttgtattta caatacatta 
16021 gaaagttaca tgatgagctt actggccaca tgttggacat gtattccgta atgctaacta 
16081 atgataacac ctcacggtac tgggaacctg agttttatga ggctatgtac acaccacata 
16141 cagtcttgca ggctgtaggt gcttgtgtat tgtgcaattc acagacttca cttcgttgcg 
16201 gtgcctgtat taggagacca ttcctatgtt gcaagtgctg ctatgaccat gtcatttcaa 
16261 catcacacaa attagtgttg tctgttaatc cctatgtttg caatgcccca ggttgtgatg 
16321 tcactgatgt gacacaactg tatctaggag gtatgagcta ttattgcaag tcacataagc 
16381 ctcccattag ttttccatta tgtgctaatg gtcaggtttt tggtttatac aaaaacacat 
16441 gtgtaggcag tgacaatgtc actgacttca atgcgatagc aacatgtgat tggactaatg 
16501 ctggcgatta catacttgcc aacacttgta ctgagagact caagcttttc gcagcagaaa 
16561 cgctcaaagc cactgaggaa acatttaagc tgtcatatgg tattgccact gtacgcgaag 
16621 tactctctga cagagaattg catctttcat gggaggttgg aaaacctaga ccaccattga 
16681 acagaaacta tgtctttact ggttaccgtg taactaaaaa tagtaaagta cagattggag 
16741 agtacacctt tgaaaaaggt gactatggtg atgctgttgt gtacagaggt actacgacat 
16801 acaagttgaa tgttggtgat tactttgtgt tgacatctca cactgtaatg ccacttagtg 
16861 cacctactct agtgccacaa gagcactatg tgagaattac tggcttgtac ccaacactca 
16921 acatctcaga tgagttttct agcaatgttg caaattatca aaaggtcggc atgcaaaagt 
16981 actctacact ccaaggacca cctggtactg gtaagagtca ttttgccatc ggacttgctc 
17041 tctattaccc atctgctcgc atagtgtata cggcatgctc tcatgcagct gttgatgccc 
17101 tatgtgaaaa ggcattaaaa tatttgccca tagataaatg tagtagaatc atacctgcgc 
17161 gtgcgcgcgt agagtgtttt gataaattca aagtgaattc aacactagaa cagtatgttt 
17221 tctgcactgt aaatgcattg ccagaaacaa ctgctgacat tgtagtcttt gatgaaatct 
17281 ctatggctac taattatgac ttgagtgttg tcaatgctag acttcgtgca aaacactacg 
17341 tctatattgg cgatcctgct caattaccag ccccccgcac attgctgact aaaggcacac 
17401 tagaaccaga atattttaat tcagtgtgca gacttatgaa aacaataggt ccagacatgt 
17461 tccttggaac ttgtcgccgt tgtcctgctg aaattgttga cactgtgagt gctttagttt 
17521 atgacaataa gctaaaagca cacaaggata agtcagctca atgcttcaaa atgttctaca 
17581 aaggtgttat tacacatgat gtttcatctg caatcaacag acctcaaata ggcgttgtaa 
17641 gagaatttct tacacgcaat cctgcttgga gaaaagctgt ttttatctca ccttataatt 
17701 cacagaacgc tgtagcttca aaaatcttag gattgcctac gcagactgtt gattcatcac 
17761 agggttctga atatgactat gtcatattca cacaaactac tgaaacagca cactcttgta 
17821 atgtcaaccg cttcaatgtg gctatcacaa gggcaaaaat tggcattttg tgcataatgt 
17881 ctgatagaga tctttatgac aaactgcaat ttacaagtct agaaatacca cgtcgcaatg 
17941 tggctacatt acaagcagaa aatgtaactg gactttttaa ggactgtagt aagatcatta 
18001 ctggtcttca tcctacacag gcacctacac acctcagcgt tgatataaag ttcaagactg 
18061 aaggattatg tgttgacata ccaggcatac caaaggacat gacctaccgt agactcatct 
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18121 ctatgatggg tttcaaaatg aattaccaag tcaatggtta ccctaatatg tttatcaccc 
18181 gcgaagaagc tattcgtcac gttcgtgcgt ggattggctt tgatgtagag ggctgtcatg 
18241 caactagaga tgctgtgggt actaacctac ctctccagct aggattttct acaggtgtta 
18301 acttagtagc tgtaccgact ggttatgttg acactgaaaa taacacagaa ttcaccagag 
18361 ttaatgcaaa acctccacca ggtgaccagt ttaaacatct tataccactc atgtataaag 
18421 gcttgccctg gaatgtagtg cgtattaaga tagtacaaat gctcagtgat acactgaaag 
18481 gattgtcaga cagagtcgtg ttcgtccttt gggcgcatgg ctttgagctt acatcaatga 
18541 agtactttgt caagattgga cctgaaagaa cgtgttgtct gtgtgacaaa cgtgcaactt 
18601 gcttttctac ttcatcagat acttatgcct gctggaatca ttctgtgggt tttgactatg 
18661 tctataaccc atttatgatt gatgttcagc agtggggctt tacgggtaac cttcagagta 
18721 accatgacca acattgccag gtacatggaa atgcacatgt ggctagttgt gatgctatca 
18781 tgactagatg tttagcagtc catgagtgct ttgttaagcg cgttgattgg tctgttgaat 
18841 accctattat aggagatgaa ctgagggtta attctgcttg cagaaaagta caacacatgg 
18901 ttgtgaagtc tgcattgctt gctgataagt ttccagttct tcatgacatt ggaaatccaa 
18961 aggctatcaa gtgtgtgcct caggctgaag tagaatggaa gttctacgat gctcagccat 
19021 gtagtgacaa agcttacaaa atagaggaac tcttctattc ttatgctaca catcacgata 
19081 aattcactga tggtgtttgt ttgttttgga attgtaacgt tgatcgttac ccagccaatg 
19141 caattgtgtg taggtttgac acaagagtct tgtcaaactt gaacttacca ggctgtgatg 
19201 gtggtagttt gtatgtgaat aagcatgcat tccacactcc agctttcgat aaaagtgcat 
19261 ttactaattt aaagcaattg cctttctttt actattctga tagtccttgt gagtctcatg 
19321 gcaaacaagt agtgtcggat attgattatg ttccactcaa atctgctacg tgtattacac 
19381 gatgcaattt aggtggtgct gtttgcagac accatgcaaa tgagtaccga cagtacttgg 
19441 atgcatataa tatgatgatt tctgctggat ttagcctatg gatttacaaa caatttgata 
19501 cttataacct gtggaataca tttaccaggt tacagagttt agaaaatgtg gcttataatg 
19561 ttgttaataa aggacacttt gatggacacg ccggcgaagc acctgtttcc atcattaata 
19621 atgctgttta cacaaaggta gatggtattg atgtggagat ctttgaaaat aagacaacac 
19681 ttcctgttaa tgttgcattt gagctttggg ctaagcgtaa cattaaacca gtgccagaga 
19741 ttaagatact caataatttg ggtgttgata tcgctgctaa tactgtaatc tgggactaca 
19801 aaagagaagc cccagcacat gtatctacaa taggtgtctg cacaatgact gacattgcca 
19861 agaaacctac tgagagtgct tgttcttcac ttactgtctt gtttgatggt agagtggaag 
19921 gacaggtaga cctttttaga aacgcccgta atggtgtttt aataacagaa ggttcagtca 
19981 aaggtctaac accttcaaag ggaccagcac aagctagcgt caatggagtc acattaattg 
20041 gagaatcagt aaaaacacag tttaactact ttaagaaagt agacggcatt attcaacagt 
20101 tgcctgaaac ctactttact cagagcagag acttagagga ttttaagccc agatcacaaa 
20161 tggaaactga ctttctcgag ctcgctatgg atgaattcat acagcgatat aagctcgagg 
20221 gctatgcctt cgaacacatc gtttatggag atttcagtca tggacaactt ggcggtcttc 
20281 atttaatgat aggcttagcc aagcgctcac aagattcacc acttaaatta gaggatttta 
20341 tccctatgga cagcacagtg aaaaattact tcataacaga tgcgcaaaca ggttcatcaa 
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20401 aatgtgtgtg ttctgtgatt gatcttttac ttgatgactt tgtcgagata ataaagtcac 
20461 aagatttgtc agtgatttca aaagtggtca aggttacaat tgactatgct gaaatttcat 
20521 tcatgctttg gtgtaaggat ggacatgttg aaaccttcta cccaaaacta caagcaagtc 
20581 aagcgtggca accaggtgtt gcgatgccta acttgtacaa gatgcaaaga atgcttcttg 
20641 aaaagtgtga ccttcagaat tatggtgaaa atgctgttat accaaaagga ataatgatga 
20701 atgtcgcaaa gtatactcaa ctgtgtcaat acttaaatac acttacttta gctgtaccct 
20761 acaacatgag agttattcac tttggtgctg gctctgataa aggagttgca ccaggtacag 
20821 tgtgctcag acaatggttg ccaactggca cactacttgt cgattcagat cttaatgact 
20881 tcgtctccga cgcagattct actttaattg gagactgtgc aacagtacat acggctaata 
20941 aatgggacct tattattagc gatatgtatg accctaggac caaacatgtg acaaaagaga 
21001 atgactctaa agaagggttt ttcacttatc tgtgtggatt tataaagcaa aaactagccc 
21061 tgggtggttc tatagctgta aagataacag agcattcttg gaatgctgac ctttacaagc 
21121 ttatgggcca tttctcatgg tggacagctt ttgttacaaa tgtaaatgca tcatcatcgg 
21181 aagcattttt aattggggct aactatcttg gcaagccgaa ggaacaaatt gatggctata 
21241 ccatgcatgc taactacatt ttctggagga acacaaatcc tatccagttg tcttcctatt 
21301 cactctttga catgagcaaa tttcctctta aattaagagg aactgctgta atgtctctta 
21361 aggagaatca aatcaatgat atgatttatt ctcttctgga aaaaggtagg cttatcatta 
21421 gagaaaacaa cagagttgtg gtttcaagtg atattcttgt taacaactaa acgaacatgt 
21481 ttattttctt attatttctt actctcacta gtggtagtga ccttgaccgg tgcaccactt 
21541 ttgatgatgt tcaagctcct aattacactc aacatacttc atctatgagg ggggtttact 
21601 atcctgatga aatttttaga tcagacactc tttatttaac tcaggattta tttcttccat 
21661 tttattctaa tgttacaggg tttcatacta ttaatcatac gtttggcaac cctgtcatac 
21721 cttttaagga tggtatttat tttgctgcca cagagaaatc aaatgttgtc cgtggttggg 
21781 tttttggttc taccatgaac aacaagtcac agtcggtgat tattattaac aattctacta 
21841 atgttgttat acgagcatgt aactttgaat tgtgtgacaa ccctttcttt gctgtttcta 
21901 aacccatggg tacacagaca catactatga tattcgataa tgcatttaat tgcactttcg 
21961 agtacatatc tgatgccttt tcgcttgatg tttcagaaaa gtcaggtaat tttaaacact 
22021 tacgagagtt tgtgtttaaa aataaagatg ggtttctcta tgtttataag ggctatcaac 
22081 ctatagatgt agttcgtgat ctaccttctg gttttaacac tttgaaacct atttttaagt 
22141 tgcctcttgg tattaacatt acaaatttta gagccattct tacagccttt tcacctgctc 
22201 aagacatttg gggcacgtca gctgcagcct attttgttgg ctatttaaag ccaactacat 
22261 ttatgctcaa gtatgatgaa aatggtacaa tcacagatgc tgttgattgt tctcaaaatc 
22321 cacttgctga actcaaatgc tctgttaaga gctttgagattgacaaagga atttaccaga 
22381 cctctaattt cagggttgtt ccctcaggag atgttgtgag attccctaat attacaaact 
22441 tgtgtccttt tggagaggtt tttaatgcta ctaaattccc ttctgtctat gcatgggaga 
22501 gaaaaaaaat ttctaattgt gttgctgatt actctgtgct ctacaactca acattttttt 
22561 caacctttaa gtgctatggc gtttctgcca ctaagttgaa tgatctttgc ttctccaatg 
22621 tctatgcaga ttcttttgta gtcaagggag atgatgtaag acaaatagcg ccaggacaaa 
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22681 ctggtgttat tgctgattat aattataaat tgccagatga tttcatgggt tgtgtccttg 
22741 cttggaatac taggaacatt gatgctactt caactggtaa ttataattat aaatataggt 
22801 atcttagaca tggcaagctt aggccctttg agagagacat atctaatgtg cctttctccc 
22861 ctgatggcaa accttgcacc ccacctgctc ttaattgtta ttggccatta aatgattatg 
22921 gtttttacac cactactggc attggctacc aaccttacag agttgtagta ctttcttttg 
22981 aacttttaaa tgcaccggcc acggtttgtg gaccaaaatt atccactgac cttattaaga 
23041 accagtgtgt caattttaat tttaatggac tcactggtac tggtgtgtta actccttctt 
23101 caaagagatt tcaaccattt caacaatttg gccgtgatgt ttctgatttc actgattccg 
23161 ttcgagatcc taaaacatct gaaatattag acatttcacc ttgctctttt gggggtgtaa 
23221 gtgtaattac acctggaaca aatgcttcat ctgaagttgc tgttctatat caagatgtta 
23281 actgcactga tgtttctaca gcaattcatg cagatcaact cacaccagct tggcgcatat 
23341 attctactgg aaacaatgta ttccagactc aagcaggctg tcttatagga gctgagcatg 
23401 tcgacacttc ttatgagtgc gacattccta ttggagctgg catttgtgct agttaccata 
23461 cagtttcttt attacgtagt actagccaaa aatctattgt ggcttatact atgtctttag 
23521 gtgctgatag ttcaattgct tactctaata acaccattgc tatacctact aacttttcaa 
23581 ttagcattac tacagaagta atgcctgttt ctatggctaa aacctccgta gattgtaata 
23641 tgtacatctg cggagattct actgaatgtg ctaatttgct tctccaatat ggtagctttt 
23701 gcacacaact aaatcgtgca ctctcaggta ttgctgctga acaggatcgc aacacacgtg 
23761 aagtgttcgc tcaagtcaaa caaatgtaca aaaccccaac tttgaaatat tttggtggtt 
23821 ttaatttttc acaaatatta cctgaccctc taaagccaac taagaggtct tttattgagg 
23881 acttgctctt taataaggtg acactcgctg atgctggctt catgaagcaa tatggcgaat 
23941 gcctaggtga tattaatgct agagatctca tttgtgcgca gaagttcaat ggacttacag 
24001 tgttgccacc tctgctcact gatgatatga ttgctgccta cactgctgct ctagttagtg 
24061 gtactgccac tgctggatgg acatttggtg ctggcgctgc tcttcaaata ccttttgcta 
24121 tgcaaatggc atataggttc aatggcattg gagttaccca aaatgttctc tatgagaacc 
24181 aaaaacaaat cgccaaccaa tttaacaagg cgattagtca aattcaagaa tcacttacaa 
24241 caacatcaac tgcattgggc aagctgcaag acgttgttaa ccagaatgct caagcattaa 
24301 acacacttgt taaacaactt agctctaatt ttggtgcaat ttcaagtgtg ctaaatgata 
24361 tcctttcgcg acttgataaa gtcgaggcgg aggtacaaat tgacaggtta attacaggca 
24421 gacttcaaag ccttcaaacc tatgtaacac aacaactaat cagggctgct gaaatcaggg 
24481 cttctgctaa tcttgctgct actaaaatgt ctgagtgtgt tcttggacaa tcaaaaagag 
24541 ttgacttttg tggaaagggc taccacctta tgtccttccc acaagcagcc ccgcatggtg 
24601 ttgtcttcct acatgtcacg tatgtgccat cccaggagag gaacttcacc acagcgccag 
24661 caatttgtca tgaaggcaaa gcatacttcc ctcgtgaagg tgtttttgtg tttaatggca 
24721 cttcttggtt tattacacag aggaacttct tttctccaca aataattact acagacaata 
24781 catttgtctc aggaaattgt gatgtcgtta ttggcatcat taacaacaca gtttatgatc 
24841 ctctgcaacc tgagcttgac tcattcaaag aagagctgga caagtacttc aaaaatcata 
24901 catcaccaga tgttgatctt ggcgacattt caggcattaa cgcttctgtc gtcaacattc 
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24961 aaaaagaaat tgaccgcctc aatgaggtcg ctaaaaattt aaatgaatca ctcattgacc 
25021 ttcaagaatt gggaaaatat gagcaatata ttaaatggcc ttggtatgtt tggctcggct 
25081 tcattgctgg actaattgcc atcgtcatgg ttacaatctt gctttgttgc atgactagtt 
25141 gttgcagttg cctcaagggt gcatgctctt gtggttcttg ctgcaagttt gatgaggatg 
25201 actctgagcc agttctcaag ggtgtcaaat tacattacac ataaacgaac ttatggattt 
25261 gtttatgaga ttttttactc ttggatcaat tactgcacag ccagtaaaaa ttgacaatgc 
25321 ttctcctgca agtactgttc atgctacagc aacgataccg ctacaagcct cactcccttt 
25381 cggatggctt gttattggcg ttgcatttct tgctgttttt cagagcgcta ccaaaataat 
25441 tgcgctcaat aaaagatggc agctagccct ttataagggc ttccagttca tttgcaattt 
25501 actgctgcta tttgttacca tctattcaca tcttttgctt gtcgctgcag gtatggaggc 
25561 gcaatttttg tacctctatg ccttgatata ttttctacaa tgcatcaacg catgtagaat 
25621 tattatgaga tgttggcttt gttggaagtg caaatccaag aacccattac tttatgatgc 
25681 caactacttt gtttgctggc acacacataa ctatgactac tgtataccat ataacagtgt 
25741 cacagataca attgtcgtta ctgaaggtga cggcatttca acaccaaaac tcaaagaaga 
25801 ctaccaaatt ggtggttatt ctgaggatag gcactcaggt gttaaagact atgtcgttgt 
25861 acatggctat ttcaccgaag tttactacca gcttgagtct acacaaatta ctacagacac 
25921 tggtattgaa aatgctacat tcttcatctt taacaagctt gttaaagacc caccgaatgt 
25981 gcaaatacac acaatcgacg gctcttcagg agttgctaat ccagcaatgg atccaattta 
26041 tgatgagccg acgacgacta ctagcgtgcc tttgtaagca caagaaagtg agtacgaact 
26101 tatgtactca ttcgtttcgg aagaaacagg tacgttaata gttaatagcg tacttctttt 
26161 tcttgctttc gtggtattct tgctagtcac actagccatc cttactgcgc ttcgattgtg 
26221 tgcgtactgc tgcaatattg ttaacgtgag tttagtaaaa ccaacggttt acgtctactc 
26281 gcgtgttaaa aatctgaact cttctgaagg agttcctgat cttctggtct aaacgaacta 
26341 actattatta ttattctgtt tggaacttta acattgctta tcatggcaga caacggtact 
26401 attaccgttg aggagcttaa acaactcctg gaacaatgga acctagtaat aggtttccta 
26461 tgcctagcct ggattatgtt actacaattt gcctattcta atcggaacag gtttttgtac 
26521 ataataaagc ttgttttcct ctggctcttg tggccagtaa cacttgcttg ttttgtgctt 
26581 gctgctgtct acagaattaa ttgggtgact ggcgggattg cgattgcaat ggcttgtatt 
26641 gtaggcttga tgtggcttag ctacttcgtt gcttccttca ggctgtttgc tcgtacccgc 
26701 tcaatgtggt cattcaaccc agaaacaaac attcttctca atgtgcctct ccgggggaca 
26761 attgtgacca gaccgctcat ggaaagtgaa cttgtcattg gtgctgtgat cattcgtggt 
26821 cacttgcgaa tggccggaca ctccctaggg cgctgtgaca ttaaggacct gccaaaagag 
26881 atcactgtgg ctacatcacg aacgctttct tattacaaat taggagcgtc gcagcgtgta 
26941 ggcactgatt caggttttgc tgcatacaac cgctaccgta ttggaaacta taaattaaat 
27001 acagaccacg ccggtagcaa cgacaatatt gctttgctag tacagtaagt gacaacagat 
27061 gtttcatctt gttgacttcc aggttacaat agcagagata ttgattatca ttatgaggac 
27121 tttcaggatt gctatttgga atcttgacgt tataataagt tcaatagtga gacaattatt 
27181 taagcctcta actaagaaga attattcgga gttagatgat gaagaaccta tggagttaga 
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27241 ttatccataa aacgaacatg aaaattattc tcttcctgac attgattgta tttacatctt 
27301 gcgagctata tcactatcag gagtgtgtta gaggtacgac tgtactacta aaagaacctt 
27361 gcccatcagg aacatacgag ggcaattcac catttcaccc tcttgctgac aataaatttg 
27421 cactaacttg cactagcaca cactttgctt ttgcttgtgc tgacggtact cgacatacct 
27481 atcagctgcg tgcaagatca gtttcaccaa aacttttcat cagacaagag gaggttcaac 
27541 aagagctcta ctcgccactt tttctcattg ttgctgctct agtattttta atactttgct 
27601 tcaccattaa gagaaagaca gaatgaatga gctcacttta attgacttct atttgtgctt 
27661 tttagccttt ctgctattcc ttgttttaat aatgcttatt atattttggt tttcactcga 
27721 aatccaggat ctagaagaac cttgtaccaa agtctaaacg aacatgaaac ttctcattgt 
27781 tttgacttgt atttctctat gcagttgcat atgcactgta gtacagcgct gtgcatctaa 
27841 taaacctcat gtgcttgaag atccttgtaa ggtacaacac taggggtaat acttatagca 
27901 ctgcttggct ttgtgctcta ggaaaggttt taccttttca tagatggcac actatggttc 
27961 aaacatgcac acctaatgtt actatcaact gtcaagatcc agctggtggt gcgcttatag 
28021 ctaggtgttg gtaccttcat gaaggtcacc aaactgctgc atttagagac gtacttgttg 
28081 ttttaaataa acgaacaaat taaaatgtct gataatggac cccaatcaaa ccaacgtagt 
28141 gccccccgca ttacatttgg tggacccaca gattcaactg acaataacca gaatggagga 
28201 cgcaatgggg caaggccaaa acagcgccga ccccaaggtt tacccaataa tactgcgtct 
28261 tggttcacag ctctcactca gcatggcaag gaggaactta gattccctcg aggccagggc 
28321 gttccaatca acaccaatag tggtccagat gaccaaattg gctactaccg aagagctacc 
28381 cgacgagttc gtggtggtga cggcaaaatg aaagagctca gccccagatg gtacttctat 
28441 tacctaggaa ctggcccaga agcttcactt ccctacggcg ctaacaaaga aggcatcgta 
28501 tgggttgcaa ctgagggagc cttgaataca cccaaagacc acattggcac ccgcaatcct 
28561 aataacaatg ctgccaccgt gctacaactt cctcaaggaa caacattgcc aaaaggcttc 
28621 tacgcagagg gaagcagagg cggcagtcaa gcctcttctc gctcctcatc acgtagtcgc 
28681 tgtaatlcaa gaaattcaac tcctggcagc agtaggggaa attctcctgc tcgaatggct 
28741 agcggaggtg gtgaaactgc cctcgcgcta ttgctgctag acagattgaa ccagcttgag 
28801 agcaaagttt ctggtaaagg ccaacaacaa caaggccaaa ctgtcactaa gaaatctgct 
28861 gctgaggcat ctaaaaagcc tcgccaaaaa cgtactgcca caaaacagta caacgtcact 
28921 caagcatttg ggagacgtgg tccagaacaa acccaaggaa atttcgggga ccaagaccta 
28981 atcagacaag gaactgatta caaacattgg ccgcaaattg cacaatttgc tccaagtgcc 
29041 tctgcattct ttggaatgtc acgcattggc atggaagtca caccttcggg aacatggctg 
29101 acttatcatg gagccattaa attggatgac aaagatccac aattcaaaga caacgtcata 
29161 ctgctgaaca agcacattga cgcatacaaa acattcccac caacagagcc taaaaaggac 
29221 aaaaagaaaa agactgatga agctcagcct ttgccgcaga gacaaaagaa gcagcccact 
29281 gtgactcttc ttcctgcggc tgacatggat gatttctcca gacaacttca aaattccatg 
29341 agtggagctt ctgctgattc aactcaggca taaacactca tgatgaccac acaaggcaga 
29401 tgggctatgt aaacgttttc gcaattccgt ttacgataca tagtctactc ttgtgcagaa 
29461 tgaattctcg taactaaaca gcacaagtag gtttagttaa ctttaatctc acatagcaat 
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29521 ctttaatcaa tgtgtaacat tagggaggac ttgaaagagc caccacattt tcatcgaggc 
29581 cacgcggagt acgatcgagg gtacagtgaa taatgctagg gagagctgcc tatatggaag 
29641 agccctaatg tgtaaaatta attttagtag tgctatcccc atgtgatttt aatagcttct 
29701 taggagaatg acaaaaaaaa aaaaaaaaaa aaaaaa 
149 
漏 
C U H K L i b r a r i e s 
_ _ _ _ _ _ 
004270440 
